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ABSTRACT 
 
EMILY WENINK BRATTON: Clinical Management and Outcomes of Patients in the Duke 
Cryptococcosis Clinical Cohort, 1996–2009  
(Under the direction of Charles Poole, PhD) 
 
Using this single-center cohort of cryptococcosis patients, we characterized temporal 
trends among HIV-infected, transplant recipients and a third heterogeneous group of HIV-
negative, non-transplant patients, over a 14-year period (1996 – 2009).  We executed a 
comparison of clinical management and predictors of poor outcomes with respect to these 
three groups.  Adherence to recommended treatment algorithms was an important research 
question in our study.  The 2010 IDSA Guidelines for treatment of these three groups was 
created to better inform clinicians, yet supportive evidence from cohort studies is still 
lacking, particularly in the HIV-negative, non-transplant group. 
All cryptococcosis patients diagnosed at Duke University Medical Center from 1996 
– 2009 were included in our study (N=207).  Although the total cases have remained steady 
(~15/year), there was a shift to a decreasing proportion of HIV-positive patients with a 
concomitant increase in HIV-negative cases, while transplant recipients remained steady.  
From the start of antifungal therapy overall mortality through one year was 25% (n=52).  
Cryptococcosis-attributable mortality through one year of follow-up was 15% (n=31); half of 
these deaths were among HIV-negative, non-transplant cases. Acute mortality was high, with 
10% of severe disease patient deaths occurring during the first two weeks from the start of 
antifungal treatment. 
iv 
As recommended, most patients with severe disease received amphotericin B for 
initial antifungal treatment and the majority of non-severe patients received fluconazole.  
Receiving a non-recommended antifungal regimen was associated with a higher relative risk 
of persistent infection at four weeks (RR1.9, 95%CI 0.9 – 4.3). The rate of attributable 
mortality among those not receiving the recommended dose of initial therapy was higher 
relative to those receiving recommended dosing (HR 2.3, 95%CI 1.0 – 5.0).  Among severe 
disease patients, flucytosine exposure was associated with a lower overall mortality rate (HR 
0.4, 95%CI 0.2 – 0.9) and attributable mortality (HR 0.5, 95%CI 0.2 – 1.2).   
The future of cryptococcosis treatment and the development of new antifungal 
therapies should not only be informed by randomized trials, but also by key observational 
trends that help to identify problematic, real-world applications of drug regimens to diverse 
populations.  
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CHAPTER I.  SPECIFIC AIMS 
 
 
The IDSA 2010 Clinical Practice Guidelines for the management of cryptococcosis 
[1]  provide informative categories for analysis by classifying patient groups (HIV positive, 
solid organ transplant recipients, and HIV-negative/non-transplant) and severity of disease 
(meningeal, non-meningeal).  Taking these categories into consideration, we examined the 
differences between the three different clinical groups and address the degree to which the 
various clinical manifestations of cryptococcosis and baseline patient immune status modify 
the effectiveness of antifungal treatment.   
The three-month mortality rate during management of acute cryptococcosis with CNS 
involvement is still nearly 20% despite medical advances and the advent of highly active 
antiretroviral therapy (HAART) [2,3,4].  In resource-limited settings, the two-week mortality 
rates after presenting to a health clinic have been reported as high as 100% [5].  With the 
high risk of mortality with severe disease, treatment and clinical management strategies are 
imperative to improving patient survival and preventing relapse or persistence of infection.   
Definitions of treatment success varies based on immune status—particularly HIV 
status.  HIV positive patients may be cured with initial therapy, with “cure” meaning the 
eradication of the fungal organism and elimination of symptoms, but early studies reveal 
rates of relapse nearing 50% [6,7,8,9].  Thus, commonly with this particular 
immunosupressed population, the goal of suppression of fungal disease without persistence 
or relapse is more realistic [3].  
 2 
With the introduction of maintenance therapy, rates of relapse have dropped 
significantly to under 10% in geographic areas where induction therapy is the standard of 
care [3,10,11,12].  A study in France comparing cryptococcosis relapse rates among HIV-
positive patients in the pre-HAART versus HAART eras found that relapse after initiating 
maintenance therapy was largely associated with a lower CD4 cell count at baseline, a slower 
rate of increase of CD4 cells in the first two weeks of HAART, as well as a serum 
cryptococcal antigen titer ≥1:512 at any time during follow-up [13].  Close monitoring of the 
patient for relapse may still be required despite this study showing that HIV patients with a 
history of cryptococcosis may be taken off maintenance therapy. Relapse rates among non-
AIDS patients are still around 15-20% [3,14].  Commonly, HIV-positive patients with 
cryptococcosis are followed indefinitely with lifelong maintenance therapy and generally 
non-HIV patients are followed for at least one year [3].   
Data is limited on predicting risk factors for failure of cryptococcal treatment.  Based 
on previous studies [13,15,16,17,18,19,20,21], some risk factors that contribute to treatment 
failure for cryptococcosis, particularly cryptococcal meningitis (the most commonly studied), 
include: positive cultures (CSF, blood), high serum or CSF antigen titers, headache, and 
abnormal mental status at admission (Table 1.1).  These suggested risk factors are not 
necessarily exhaustive, nor do they represent a consensus among the medical community.  
Questions remain about optimal treatment strategy for patients given a particular set 
of risk factors.  Previous studies have shown that treatment is generally 50-80% (median: 
63%) effective, antifungal drugs cause toxicities in roughly one-third of cases, and mortality 
while on antifungal therapy still remains high (approximately 20%) [3,4,13,18,22]. This 
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mortality rate is not necessarily due to cryptococcosis, but can be a result of an underlying 
condition or co-infection.   
 
Study Rationale 
 
Cryptococcus is an invasive mycosis that causes considerable morbidity and 
mortality, but there are few larger cohort studies that focus on this disease, many of which 
are now more than a decade old [13,18,19].  With the global burden of cryptococcal infection 
reaching 1 million cases per year [23], many questions remain regarding the clinical 
management on of HIV-infected individuals, organ transplant recipients and more recently 
immunocompetent individuals or other non-HIV/non-transplant hosts.   
Many HIV positive patients are on lifelong antifungal maintenance therapy with 
monthly monitoring.  Therefore, identifying risk factors and treatment recommendations for 
HIV patients with cryptococcal disease is important not only for the potential prevention of 
immune reconstitution inflammatory syndrome, increased intracranial pressure, drug 
resistance and cryptococcomas, but also to identify the optimal treatment regimens of 
cryptococcal disease to reduce costs associated with treatment failure.  This is particularly 
true in resource limited settings coping with the HIV epidemic without proper access to 
diagnostic tools or medications.  Due to the absence of new drug development, there is much 
need for well-supported disease management strategies.   
This is the first comprehensive, single-center observational cohort in the U.S. devoted 
to the in-depth examination of cryptococcosis among both the HIV-infected and non-HIV 
patient. It is the first database generated from a single medical center that will contain a 
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wealth of information on all three clinical groupings defined by the Infectious Disease 
Society of America (IDSA) [1] that include: 1) HIV-infected individuals; 2) solid organ 
transplant recipients; 3) non-HIV and non-transplant hosts.  The third group is notably 
heterogeneous, but will most likely form the smallest proportion of patients in this database, 
although this group could prove of unique interest to clinicians and to serve as a comparison.   
 
Specific Aim 1.  How do the following three groups with cryptococcosis differ with respect 
to clinical presentation and management:  HIV-positive, transplant recipients, and HIV-
negative/non-transplant patients?  
Objectives:   
1. Examine the changing populations for acquiring Cryptococcus (HIV positive, 
transplant recipients, HIV-negative/non-transplant) 
 
2. Summarize temporal trends in diagnosis and amphotericin B formulations as 
initial therapy 
 
3. Describe and assess differences and similarities of underlying three groups with 
respect to initial presentation, diagnostics and approaches to clinical management 
a. Examine prevalence and type of immunosuppression in the three groups—
HAART exposure in HIV-infected patients, corticosteroid use and 
immunosuppressive agents among transplant and HIV-negative/non-
transplant, as well as prevalence of patients appearing 
“immunocompetent.” 
 5 
Specific Aim 2.  How does initial antifungal therapy for cryptococcosis influence patient 
outcomes of persistence of infection, attributable mortality and overall mortality? 
 
Objectives:   
1. Determine the association of aspects of initial treatment on poor patient outcomes that 
include the risk of persistent infection and rates mortality due to cryptococcosis and 
overall 1-year mortality  
a. Estimate the effect of initial antifungal treatment type on persistence and 
mortality 
b. Estimate the effect of initial treatment dosing on persistence and mortality 
c. Estimate the effect of flucytosine exposure among patients with severe 
cryptococcosis disease on persistence and mortality 
i. Estimate the effect of ≤ 7 days or >7 days of flucytosine on the risk of 
persistence and mortality rate among patients surviving at least 14 
days from the time of cryptococcosis diagnosis. 
 
2. Assess other strong predictors for the above outcomes in (1). 
 
3. Report the frequency of secondary outcomes of Immune Reconstitution Inflammatory 
Syndrome (IRIS), renal toxicity measured by at least a 50% decline in Glomerular 
Filtration Rate (GFR), re-induction of antifungal therapy, and changing antifungal 
therapy during initial induction. 
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Table 
Table 1.1.  Indicators of risk for failure (including mortality) of cryptococcosis antifungal 
treatment. 
Non-HIV Infected HIV-infected 
Positive India ink 
High LP OP 
Low CSF glucose 
Extra-neural sites 
CSF antigen titer >1:32 
CSF antigen titer ≥1:1024 
Steroid therapy 
Lymphoreticular malignancy 
Hematologic malignancy 
No headache 
Organ failure 
Abnormal mental status 
Low CSF leukocyte count
a 
Absent antibody
a 
Age ≥60 
Male gender 
Positive culture at 2 weeks 
Positive blood and urine cultures 
Treatment without flucytosine 
High serum or CSF antigen titer 
Age >30 years 
Low CSF glucose 
Intravenous drug use
a
 
High MIC to fluconazole
b
 
Mechanical ventilation
a
 
ICU admission
a
 
Organ failure 
a
 These risk factors were not measured in our study and will be uncontrolled in our analyses; CSF 
nucleated host cell count was used as a proxy for CSF leukocyte count  
b
 High MIC to fluconazole or other antifungal drugs were measured very infrequently and 
will unlikely be included in our study as a risk factor for treatment failure. 
  
CHAPTER TWO - BACKGROUND AND SIGNIFICANCE 
 
 
Cryptococcus spp., an encapsulated yeast, is an opportunistic human fungal pathogen 
isolated from the environment worldwide, particularly in urban areas [24,25].  Humans are 
thought to be exposed by inhaling the fungal basidiospores, which are small enough to 
establish in the alveoli of the lung [26].  Pigeon guano is a common source for infectious 
propagules of C. neoformans and is postulated to play a central role in transmission from the 
environment to humans [3,24,27,28,29,30,31,32,33].  As the spores are inhaled, the lungs are 
the portal of entry and pneumonia is a common manifestation of cryptococcal diseases, 
however, the most common manifestation of disease is when the pathogen spreads to the 
central nervous system (CNS) and causes meningoencephalitis.  This is more common 
among immunocompromised individuals who are unable to contain the infection at the 
primary site (the lung) and from the advent of the HIV epidemic, C. neoformans has become 
an increased global concern among those who are HIV infected [34].  Furthermore, 
cryptococcal meningitis is uniformly fatal without treatment [3,24,35,36,37].   
Cryptococcosis refers to invasive C. neoformans infections.  C. neoformans exists in 
two varieties— grubii (serotype A) and neoformans (serotype D) [36].  Both of these C. 
neoformans varieties cause disease predominantly in immunocompromised individuals [36].  
However, serotype A is identified in more than 95% of clinical cryptococcosis isolates from 
immunocompromised patients [3,24,25,35].  In the late 1990’s Cryptococcus gattii emerged 
in Vancouver Island, British Columbia, Canada, resulting in an outbreak of infections in both
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immunosuppressed, and more often than C. neoformans, immunocompetent humans and 
animals [38,39].  C.gattii is rare in the Southeastern U.S. with only one identified clinical 
case in an immunocompromised adult [40], hence this species was not the focus of our study.   
Diagnosis without laboratory capabilities is difficult because clinical presentation of 
human cryptococcosis can be very nonspecific.  However, the central nervous system (CNS) 
and respiratory tract are the most common organs involved in cryptococcal infection [34].  
Clinical manifestations have a wide range of severity from an asymptomatic nodule in the 
lung to sudden death from septic shock with acute respiratory distress syndrome. Clinical 
signs can be seen in the CNS, lung, skin, eye, genitourinary tract, bone and joints, muscle, 
heart, gastrointestinal tract, breast, lymph nodes, thyroid, adrenal gland, and head and neck 
[3].   
Cryptococcosis can occur at any age.  Being at least 30 years of age is reported as a 
risk factor for cryptococcosis treatment failure among HIV positive individuals [41,42], 
while cases that are ≥60 years are reported among HIV-negative patients [21].  Age may 
have an independent impact on survival or incidence of treatment failure.  A male 
predominance exists in both HIV positive and HIV negative cryptococcosis patients 
[4,41,43,44].   
 
Disease populations—the three groups  
 
The 2010 IDSA Cryptococcal Guidelines defined three distinct risk groups for 
induction treatment of cryptococcosis [1]:  (1) HIV-positive; (2) transplant recipients; and (3) 
a heterogeneous group with neither of these conditions (i.e., HIV-negative/non-transplant).   
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HIV Positive  
 
Cryptococcal infections in HIV-positive patients almost always occur in advanced 
stages of the disease, and are for the most part, incurable but treatable— individuals who 
survive initial illness require lifelong maintenance therapy and close monitoring [3].  
Symptoms and clinical findings common in AIDS patients include: headaches, fever, shorter 
duration of symptoms than non-AIDS patients, positive India ink examination, cerebrospinal 
fluid (CSF) antigen titer ≥1:1024, CSF pleocytosis <20/l, CD4 counts <100 cells/l, serum 
antigen positive, cryptococcemia and increased intracranial pressure (Table 2.1) 
[3,6,7,8,9,45,46].  There is less knowledge on common symptoms among HIV-negative 
patients, but similar to HIV-positive patients headache, fever and abnormal CSF chemistry 
(glucose <40, protein >45) are considered most common (Table 2.1) [45]. 
Parallel with the rise of the AIDS epidemic in 1981, the incidence of cryptococcosis 
increased [3].  Before the HIV epidemic, cryptococcosis was much more uncommon and 
occurred predominantly among patients with compromised immunity, such as those with 
hematologic malignancy or had undergone solid organ transplantation at a rate of 0.2 – 0.8 
per 100,000 depending on geographic area [34,47].  In more recent decades, HIV-associated 
cryptococcal infection is estimated to account for up to 80% of all cases [34,47,48].  It is 
estimated the current rate of HIV-associated cryptococcosis is approximately 1 million cases 
per year worldwide [23].  Despite this high estimate of disease, the incidence among 
HIV/AIDS patients has fallen since the early 1990’s in the United States, with two cities 
(Houston, TX and Atlanta, GA) reporting drops in incidence from 24 per 1000 and 66 per 
1000 in 1993/1992 to 2 per 1000 and 7 per 1000 in 2000, respectively [42].  This pattern of 
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observation was also made in a large retrospective study in France, with a 46% decrease in 
cryptococcosis incidence between pre-HAART and post-HAART eras [41].   
Incidence rates of cryptococcosis remain the highest in areas where HIV disease is 
high and availability of highly-active antiretroviral therapy (HAART) is limited [1,23].  
About 5-10% of patients with AIDS in the United States will develop cryptococcosis 
(pulmonary and/or meningeal) [1,3].  Prevalence estimates among HIV patients in the U.S. 
range from 5-13% depending on region and study year (1985-1997) [3,6,7,8,9,49,50,51].  In 
an eight-year surveillance study in the United States, under one-third of the HIV-infected 
cryptococcosis cases had been placed on HAART before diagnosis [42], emphasizing the 
importance of access and adherence to HAART in prevention of opportunistic disease, not to 
mention being tested for HIV infection.  Though progress has been made, the 3-month 
mortality rates from acute cryptococcal meningitis continue to hover around 20% [2,4].   
 
Solid Organ Transplant  
 
The risk of cryptococcosis has not vanished  in developed countries because of the 
increased use of immunosuppressive therapy and continued progress of transplant medicine 
[34]. Cryptococcosis is the third most common invasive fungal infection affecting solid 
organ transplant recipients, with a mortality rate of 10-20% and near 40% with CNS 
involvement [43,52,53,54].  With the advancement in solid organ transplantation and potent 
immunosuppressive drugs, rapidly altering the immune system can put patients at risk for 
cryptococcal disease and Cryptococcus-associated immune reconstitution inflammatory 
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syndrome (IRIS) [43].  Between 20-60% of cryptococcosis in HIV-negative patients occurs 
in solid organ transplant patients [3,21,47,55].   
Cryptococcosis disease is diagnosed at a median of 21 months after transplantation 
[56] and most commonly in renal transplant patients; though liver transplant patients are 
more likely to have disseminated disease [56].  Studies have reported a lifetime 
cryptococcosis prevalence of 3-4% post-transplantation [52,57,58,59].  Immunosuppressive 
drug administration for transplant recipients to prevent organ rejection can place them at 
increased risk for cryptococcal infection.  Corticosteroid use is associated with an increased 
risk of cryptococcosis [16,43,60].  The use of calcineurin inhibitors as an immunosuppressive 
agent appears to be associated with lower mortality, but the interaction of this class of drug 
with amphotericin B deoxycholate (AmpBd) can contribute to nephrotoxicity [3,61].  
Therefore, lipid formulation amphotericin B (LFAmpB) is recommended for organ transplant 
recipients (Table 2.2).  A study by Sun et al (2009) demonstrated that LFAmpB was 
significantly associated with better survival in transplant patients compared to AmpBd (OR, 
0.11; 95% CI, 0.02-0.57) [61].    
 
HIV-negative, non-transplant 
 
The healthy human population is rarely infected by cryptococcosis, but cases with 
limited frequency have been reported [3,4,21,62].  High risk patients other than HIV-positive 
individuals and organ transplant recipients are a heterogeneous group.  Patients with 
malignancies, specifically those in the classical tumor risk groups (Hodgkin’s disease, 
lymphoma, and chronic leukemia) are considered high risk [3,14,63,64,65,66,67].  Diabetes 
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or chronic lung diseases may contribute to susceptibility, and simultaneous infection with 
other fungi cannot be ruled out [3].  There are still many questions surrounding this patient 
group, particularly with risk factors for cryptococcosis disease given their “healthy” immune 
status.  Therapeutic approaches are primarily based on expert opinion, out-dated explorative 
and retrospective cohort studies.  Lacking a consensus, further study is needed.  
 It is difficult to consistently treat such a diverse group with mortality rates still as 
high as 24% [19,22].  More studies to inform the management of the HIV-negative/non-
transplant group and to understand how host immunity plays a role in poorer prognosis are 
needed so as to reduce observed elevated mortality in this group.  In an important study by 
Pappas et al (2001), 306 HIV-negative cryptococcosis patients from 15 different centers in 
the U.S. were shown to have successful treatment in 74% of cases.  Relapse occurred in 4% 
of patients, all-cause mortality was 30% and death due to cryptococcosis was 12% [21].  
Factors influencing mortality among all patients included organ failure, hematologic 
malignancy, age ≥60 years, unsuccessful therapy, site of infection other than pulmonary and 
a positive blood culture for C. neoformans (Table 2.1) [21].  A recent multi-center study of 
86 cryptococcal meningitis patients also found the highest mortality in the non-
immunosuppressed group (46%) compared to immunosuppressed (19%) and HIV-positive 
(15%) cryptococcal meningitis patients [62], and previous studies have reported 30 - 44% 
overall mortality in the HIV-negative population [21,68,69,70], and in one of these studies 
this was compared to a 22% mortality among HIV-positive patients [69].  However, a couple 
of these studies included C.gatii cases, which many have influenced rates of poor outcome 
[69,70].   
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Diagnostics  
 
 India ink stain (direct observation) 
 Latex agglutination test (antigen detection) primarily in CSF and serum 
 Culture (24-72 hours up to 5-7 days) 
 
Cryptococcus neoformans can be rapidly diagnosed with an India ink stain of the CSF 
fluid.  It is not as sensitive or specific as serological tests, but serves more as an immediate 
diagnostic tool that can also reveal a general idea of organism burden.  The detection of the 
cryptococcal polysaccharide antigen in body fluids (latex agglutination test) is another highly 
sensitive and specific (~95%) method to identify infection and indicate fungal burden.  A 
high antigen titer level (≥1:1024) translates into a higher burden of organisms.  Generally, the 
CSF is tested to rule out meningoencephalitis and the serum is tested for disseminated 
disease using the antigen test.  Other body fluids can be tested, such as urine or pulmonary 
fluids.  In geographic areas with a high burden of HIV, the serum cryptococcal antigen is 
now being evaluated as a screening tool for patients at-risk for cryptococcosis.  Culturing 
Cryptococcus neoformans is another diagnostic tool, but takes longer than the other two tests, 
and CSF cultures for viable organisms may be difficult if there is a case of chronic 
cryptococcosis (low fungal burden in the CSF) and after treatment has started (India ink is 
positive but yeast is not viable).   
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Treatment 
 
Before 1950 cryptococcosis was uniformly fatal, however its treatment has improved 
dramatically in the last 20 years [1,3].  There was a dramatic rise in cryptococcal infections 
in parallel with the AIDS epidemic in the early 1980’s. The widespread use of fluconazole 
for antifungal prophylaxis is thought to be a contributing factor of the decline in incidence 
beginning in the early-mid 1990s [47]. Currently the most common antifungal therapies used 
to treat cryptococcal disease are:  amphotericin B (a polyene antimycotic) and flucytosine, 
fluconazole, and lipid formulations of amphotericin B.  These drugs are used alone or in 
combination therapy dependent on the underlying disease state [1].  Success of treatment 
varies due to a lack of randomized clinical trials; selection of a treatment regimen is largely 
arbitrarily decided by the prescribing physician [1]. 
Treatments have been more widely studied among HIV-related cryptococcal disease, 
as many of these patients must receive lifetime antifungal therapy.  Side effects of 
combination therapy are rather common in this immunocompromised group and despite 
advances, mortality associated with cryptococcal meningitis can be up to 25% among 
persons with AIDS [15].  For HIV-positive patients with a cryptococcal infection that has no 
CNS involvement, the goal of treatment is preventing dissemination through drug regimens 
that vary based on symptom presentation and culture results [15].  Therapy for cryptococcal 
meningitis aims to lower elevated intracranial pressure and eradicate the infection (though 
eradication is uncommon in those with HIV) [15].  More often, the goal is long-term 
suppression of infection and resolution of clinical signs and symptoms of disease [15].   
Flucytosine is commonly used in combination with fluconazole or amphotericin B to treat 
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cryptococcal meningitis in patients with AIDS, despite the substantial danger of drug-related 
toxicities and fluconazole resistance [15].   
Amphotericin B 
 
Amphotericin  B (AmpB) began as cryptococcal therapy in 1956 [71] and to date, is 
the most potent and effective drug for treating cryptococcal meningitis with success rates 
ranging between 60-70% [3].  This drug is limited by its poor penetration of the subarachnoid 
space accompanied risk of nephrotoxicity; therefore it is commonly administered in 
combination with flucytosine or fluconazole [3,72].  Amphotericin B is also available in 
more expensive lipid formulations (LFAmpB) that reduce the risk of renal toxicity and thus 
allow higher doses to be administered (3-6mg/kg/day for liposomal AmpB [L-AmpB] or 
amphotericin lipid complex [ABLC] 5mg/kg/day).  Lipid formulations are also beneficial in 
patients with baseline renal concerns [1,3]. Optimal dosing of LFAmpB and effectiveness in 
combination therapy are still unclear.  There is some evidence that LFAmpB at 4mg/kg/day 
is equal or more fungicidal than AmpBd [1,73,74].  Human studies are still undersized, 
making clear recommendations for treatment difficult.  
 
Flucytosine (5FC) 
 
5-Fluorocytosine (flucytosine) was initially used to treat cryptococcal meningitis as a 
single drug therapy, but resistance and consequent patient relapse were quickly identified 
[75,76,77].  Combined with amphotericin B, it has synergistic or additive effects [13,78].  
This has the benefit of lowering the dose of AmpBd to address toxicity issues [18,22].  In 
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AIDS patients it has been demonstrated that antifungal regimens containing flucytosine is an 
independent predictor of treatment success [13,78].  This drug is not without some serious 
drawbacks that generally arise between days 4-14 of treatment [79].  Side effects include 
bone marrow suppression, leucopenia and gastrointestinal disturbances [80,81].  Eliminated 
primarily by the kidneys, changes in renal function should also be checked [3].  Drug levels 
should be monitored to avoid bone marrow toxicities, with therapeutic ranges between 30-80 
µg/ml (and not exceed 100µg/ml) two hours after first recommended dose of 100 mg/kg/day.  
This dose was found effective by van der Horst et al. (1997) with only a 3% withdrawal rate 
[13].  It is still uncertain what drug levels correspond with gastrointestinal side effects and 
pancytopenia.   
 
Fluconazole 
  
Fluconazole is the backbone of many cryptococcosis treatment regimens. It is 
recommended as primary therapy for mild or moderate cryptococcosis and consolidation 
therapy/maintenance therapy for severe cryptococcosis [1].  Fungistatic (not fungicidal) 
against C. neoformans, it remains an attractive treatment choice because of its availability, 
affordability and tolerability.  Long-term use of fluconazole for prophylaxis or suppression 
has led to higher minimum inhibitory concentrations (MICs) and increasing resistance in 
parallel with the AIDS pandemic [82,83,84,85].  Factors also contributing to relapse among 
patients on fluconazole are non-compliance to therapy as well as severe immunosuppression 
resulting in uncontrolled fungal burden.   
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Treatment Recommendations 
 
Treatment recommendations based on the most recent 2010 IDSA Guidelines for 
effective treatment of cryptococcosis according to each category of presentation of 
cryptococcosis are in Tables 2.1 and 2.2 [1].  Proper induction therapy for cryptococcal 
meningoencephalitis was defined using the categories in Table 2.1.  For pulmonary or other 
types of cryptococcosis, appropriate therapy was defined by IDSA recommendations in Table 
2.2 [1]. 
Fluconazole, flucytosine and amphotericin (deoxycholate or lipid preparation) are the 
antifungal medications that comprise the 2010 IDSA Guidelines for effective treatment of 
cryptococcosis and were also primary treatments recommended for use in the previously 
published 2000 guidelines [1,15].  These four drugs are sometimes used in combination or 
alone (except for flucytosine, which is not given alone), and choice of treatment relies on the 
severity of disease, immune and HIV status, and other possible underlying conditions.  They 
are the same four treatments used and available to patients dating back to the beginning of 
our cohort study in 1996; part of the reasoning for our study period range along with the 
availability of HAART among HIV infected patients.  Interestingly and considering their 
long history of use, there have been very few reports of drug-resistant strains (either azole or 
polyene) of C. neoformans [86].  
 
Clinical management 
 
Aside from effective antifungal treatment, the prognosis for cryptococcal meningitis 
relies on the underlying disease, burden of organisms, symptoms at presentation, and host 
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inflammatory reactions [34].   Management of patients with severe disease that have elevated 
intracranial pressures (≥ 20 – 25 cm water) is important in preventing poor outcome, but its 
requirement in conjunction with symptom development (e.g., increasing headache, mental 
status changes, new neurologic findings) and a precise opening pressure for treatment has not 
yet been established [34].  One study of HIV patients with cryptococcal meningitis showed 
elevated pressures two weeks after starting treatment predicted poor clinical response [15], 
however another study did not find a significant association between opening pressure at day 
14 and mortality at 10 weeks [87].  A recent study found increased intracranial pressure was 
more common among HIV-infected (49%) and non-immunosuppressed (67%) 
cryptococcosis patients compared to immunosuppressed patients.  However, HIV-patients 
were more likely to receive repeat lumbar punctures that other patient groups [62].  Options 
for managing acute elevated intracranial pressure include: repeated lumbar punctures, lumbar 
drain insertion, ventriculostomy, or ventriculoperitoneal shunt.  In patients who have IRIS, 
corticosteroids are needed to control symptoms [34].   
Resolution of signs and symptoms of patients who have cryptococcal meningitis 
should resolve within two weeks after starting antifungal therapy [34].  A study found that 
patients who do not have negative CSF cultures by day 14 have a five times higher risk for 
treatment failure at 10 weeks of follow-up than those with negative cultures [88].  The 
baseline organism load and rate of clearance of organisms in the CSF is an important factor 
in patient outcome.  A recent study demonstrated that CSF cryptococcal colony-forming unit 
(CFU) counts and CSF cryptococcal antigen titers are highly correlated at baseline [89].  CSF 
cryptococcal CFU counts decreased readily during the first 2 weeks of treatment, although no 
correlation occurred between the rate of decline in CSF cryptococcal CFU counts and drop in 
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CSF cryptococcal antigen titers [89].  Both of these measures can serve as a measure of 
organism load and can be used in follow-up evaluation after cryptococcal treatment.  A larger 
combined cohort study of 262 HIV-infected cryptococcal meningitis cases found an 
association between the rate of clearance of infection and survival [90].   The strength of the 
association in multivariate analysis was stronger with survival at 2 weeks (HR 1.34; 95% CI, 
1.06–1.68) than at 10 weeks (HR 1.18; 95% CI, 1.04–1.33) [90].  
 
Immune reconstitution inflammatory syndrome (IRIS) 
 
 Rapid changes in immunity, such as with the introduction of HAART among HIV-
infected patients, can result in a clinical worsening or radiographic manifestations consistent 
with an inflammatory process but produces negative results for biomarkers or cultures [34].  
Referred to as IRIS, this condition has been reported in up to one-third of HIV patients with 
cryptococcosis upon initiation of HAART [91].  Timing of onset varies, generally 4 – 6 
weeks after starting HAART and is associated with increasing CD4 counts and diminishing 
viral load [91,92].  There is evidence that IRIS is more common in patients with a higher 
fungal burden and disseminated infection or fungemia [91,93].  The recommendations on 
when to begin HAART following cryptococcosis infection vary widely between 2 – 10 
weeks [1]. 
 Not limited to HIV-infected cryptococcosis patients, IRIS has been observed in 5% of 
solid organ transplant recipients nearly 6 weeks (range, 4 – 12 weeks) from the start of 
antifungal therapy [93].  More potent immunosuppressive therapy has been shown to be a 
risk factor for IRIS in this population [94].   Similar risk factors to HIV patients, such as high 
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fungal burden, influence the development of IRIS, and graft survival is also reduced in this 
patient group [95].  Management of IRIS in transplant recipients and other 
immunosuppressed groups, as well as apparently “normal” hosts can be complex as it is 
difficult to diagnose and treat as clinicians want to cure fungal disease without a strong host 
immune response [34]. 
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Tables 
 
Table 2.1.  Primary therapy recommendations for cryptococcal meningoencephalitis based on 
the 2010 IDSA Guidelines [1]. 
Underlying condition Primary induction therapy Maintenance therapy  
HIV-positive  
 
  
 AmpBd (0.7 – 1.0 mg/kg/d IV)a 
plus 5FC (100mg/kg/d po) for at 
least two weeks  
Fluconazole 400mg (6mg/kg) po 
daily for a minimum of 8 weeks, 
then fluconazole 200mg po daily 
≥1yrb 
Organ transplant 
recipients 
  
 Liposomal AmpB 3-6mg/kg/d IV 
or ABLC 5mg/kg/d IV plus 5FC 
100mg/kg/d for at least 2 weeks 
Fluconazole 400-800mg po daily 
for 8 weeks; followed by 
fluconazole 200mg po daily for 
6-12 months 
HIV-uninfected, non-
transplant  
  
 
 
 
 
 
AmpB deoxycholate ≥0.7 – 
1.0mg/kg/d + 5FC (if tolerant) 
100mg/kg/d for ≥4 weeks, ≥6 
weeks if intolerant to flucytosine 
Fluconazole 400mg po daily for 
8 weeks; followed by 
fluconazole 200mg po daily for 
6-12 months 
a 
Can substitute amphotericin B deoxycholate for lipid formulations AmpB (3-6 mg/kg/d) for at least 
2 weeks if patients have or are predisposed to renal dysfunction 
b 
Dependent upon the following:  successful introduction of HAART, CD4 ≥ 100cells/l and negative 
HIV viral load for ≥3 months with minimum of 1 year of antifungal therapy  
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Table 2.2.  Primary therapy recommendations for non-meningeal cryptococcosis (pulmonary 
or other) adapted from the 2010 IDSA Guidelines [1]. 
Underlying condition Characteristics of disease Treatment 
Immunosuppressed 
patients 
  
 Pneumonia associated with 
CNS or evidence of 
dissemination and/or ARDS
a
  
 
Treat like CNS disease (Table 
2.1) including maintenance 
therapy; due to risk of 
nephrotoxicity, AmpBd is not 
recommended for first line 
therapy (LFAmpB should be 
used)
b
 
Immunocompetent   
 No evidence of dissemination, 
mild-to-moderate symptoms, 
absence of diffuse pulmonary 
infiltrates, absence of severe 
immunosuppression 
Fluconazole 400mg/d for at least 
6-12 months 
 
 Severe disease Treat like CNS disease (Table 
2.1) including maintenance 
treatment 
 
 Mild to moderate symptoms Fluconazole 400mg daily for 6-12 
months 
a
 ARDS = Acute Respiratory Distress Syndrome 
b
 Recommendation for organ transplant recipients.  Immunosuppressive management should include:  
sequential or step-wise reduction of immunosuppressants – lowering corticosteroids dose first 
(recommendation based on expert opinion with moderate evidence). 
  
  
CHAPTER III.  RESEARCH DESIGN AND METHODS 
 
Study Population 
 
The clinical cohort used for this study originates from the Duke University Medical 
Center (DUMC) in Durham, North Carolina in the Southeastern United States.  During the 
study period from January 1, 1996 through October 31
st
, 2009 we retrospectively collected 
demographic and clinical information on all adult patients discharged from DUMC with 
ICD-9 diagnosis codes of cryptococcosis, cryptococcal meningitis, pulmonary Cryptococcus, 
and disseminated Cryptococcus.  Subjects were considered eligible if they had confirmed 
cryptococcal disease and received treatment for their cryptococcal infection at DUMC with a 
sufficient electronic medical record or paper chart available for review.  The complete 
medical record for each patient was reviewed and data regarding different interventions and 
outcomes were extracted.  Investigators recorded all data on a standardized abstraction form 
that was reviewed by an epidemiologist and clinician prior to and during data entry.  
Abstraction forms were entered in to Microsoft Office Access (2007) and data analysis was 
performed using SAS v9.2 (SAS Institute, Cary, NC).  This study including primary data 
collection was approved by the Duke University Medical Center IRB.  Secondary data 
analyses required for Chapters Four and Five were approved by the UNC-Chapel Hill IRB 
and the Duke Medical IRB.
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Definitions and Data Collection 
 
A cryptococcosis case was confirmed by having at least one of the following:  
positive cerebral spinal fluid (CSF) antigen or fungal culture, direct histological examination 
of Cryptococcus, positive serum cryptococcal antigen (CRAG) test, or positive culture from 
blood or pulmonary sites.  Positive CSF India ink staining alone was not an acceptable 
diagnostic tool, but was used for supportive evidence for infection. 
Basic demographics, such as age, gender, state of residence, and race/ethnicity were 
collected.  Although race and gender are possibly associated with cryptococcosis disease, 
HIV status, or organ transplant receipt, there is no strength of evidence that these 
demographics are associated with which antifungal induction treatment a patient is given, but 
other factors such as immunosuppression and severity of cryptococcosis, are more important 
predictors of what antifungal regimen is chosen.   
Upon the first admission for cryptococcosis, patient information regarding presenting 
symptoms, self-reported duration of symptoms and radiological findings (brain CT, brain 
MRI, chest CT and chest X-ray) were recorded closest to the date of diagnosis.  Abnormal 
radiology was defined as evidence of hydrocephalus, gyral enhancement, and/or multiple 
nodules that may be enhancing or non-enhancing [96].  Nodules can be either single or 
multiple [97].    Demographic information included birth date, race/ethnicity, gender, and 
country of origin if not the United States.  Patient weight (kg) closest to first cryptococcosis 
diagnosis was recorded to assess accurate antifungal dosing.   
For HIV-positive patients, last CD4 count prior to cryptococcosis diagnosis was 
recorded along with all subsequent CD4 counts until “lost to follow-up” or death.  Also noted 
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were:  the date of HIV diagnosis, any documented evidence of non-compliance with 
antiretroviral (ARV) therapy and/or antifungals, whether cryptococcosis was an AIDS-
defining illness, and the use of ARV therapy before, during and after cryptococcosis 
diagnosis until lost to follow-up or death. 
Information on solid organ transplant recipients included:  date and type of transplant, 
if they experienced graft-versus-host disease (GVHD) status ≤6 months after transplant, and 
type and dose of immune suppression medications at the time of cryptococcosis diagnosis 
(corticosteroid, calcineurin inhibitor, glucocorticoid, monoclonal antibodies, methotrexate, 
sirolimus, mycophenolate mofetil, azathioprine, or other).  It was also noted if these drugs 
were changed or stopped due to cryptococcosis disease.  There was one patient with a stem 
cell transplant (not solid organ) that was included in this immunosuppressed transplant 
group.   
Regardless of whether patients had HIV or received and organ donation, other 
possible causes of immune suppression (hematological or other malignancy, rheumatologic 
disorder, chronic organ failure, or steroid therapy) were noted. If there was no apparent 
immunosuppression, patients were classified as “immunocompetent.”   
Clinical data in existence as of October 31
st
, 2009 was collected. The study period 
spanned the time patient was followed up at DUMC following the diagnosis of cryptococcal 
infection.  Starting at the first admission for cryptococcosis and continuing through all 
subsequent available follow-up time, investigators recorded lumbar puncture data (opening 
pressure, RBC, number of nucleated cells, glucose, CSF antigen titer, CSF culture positivity, 
India ink stain, and antifungal MIC), serum cryptococcal antigen titers, blood and pulmonary 
fungal cultures, and other sites positive for Cryptococcus.  For every LP performed, values 
 26 
for collection tube #4 were recorded, and if not available, the highest tube number was used 
for LP data.  Co-morbid infections, positive cultures for other organisms and new cancer 
diagnoses were noted during the time of hospitalization or while on treatment for 
cryptococcosis.  Creatinine levels and positive culture results were recorded at each 
admission, after induction therapy, and at 2 weeks, 10 weeks, 1 year and >1 years of follow-
up.  Peak creatinine was recorded while the patient was on induction therapy.  All available 
flucytosine serum drug levels were obtained.   Hematologic parameters (hemoglobin, 
hematocrit, WBC count and platelets) at the start date of flucytosine treatment and at the 
nearest available date with valid measurements 14 days after starting flucytosine were 
collected.  Treatment information (type, dose and date of start and date of stopping) was 
abstracted from the first admission for cryptococcosis until lost to follow-up, death or until 
the end of the study period.    
Organ failure before, during and after antifungal therapy was an important variable 
collected in this study, particularly transplanted organ failure during or after antifungal 
therapy among transplant recipients.  Poor clinical response either from treatment failure 
(persistence of clinical findings or positive microbiology) or treatment toxicity (notably renal 
failure) was noted along with modifications made to treatment due to these adverse events.  
Date of death and death due to cryptococcosis were also recorded.  
In a paper by Seagal et al (2008), authors proposed guidelines for defining treatment 
responses and study outcomes to invasive fungal diseases in clinical trials (Table 3.1) [98].  
These recommendations informed our study definitions used for persistence of 
cryptococcosis.  Although the guidelines only address treatment response in cryptococcal 
meningitis cases (CNS disease), we have extrapolated these definitions for this study to 
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include success and failure in non-CNS cases.  “Relapse” was defined as clinical, 
mycological or radiographic evidence of recrudescence after stopping antifungal therapy, if 
the patient had initially experienced “success” [21]. 
Figure 3.1 is a conceptual diagram of cohort patient flow from first diagnosis (1) and 
admission for cryptococcosis through death or lost to follow-up. After diagnosis, patients are 
typically started on treatment immediately—sometimes even prior to positive culture results 
if clinical signs indicate cryptococcosis disease (2).  Treatment exposure depends on multiple 
factors and recommendations for treatment are listed in Tables 2.1 and 2.2.  Two major 
considerations for treatment shown in these tables are HIV status or alternate possible 
immunosuppression and CNS involvement.  Patients will then either: die while on treatment 
(2a), fail therapy due to toxicity or persistence of disease (2b), or experience mycological 
cure or suppression (3).  Patients cured or suppressed on maintenance therapy (3) are 
followed until they die or are lost to follow-up.  Some patients will experience relapse (3a) 
and have to restart antifungal maintenance therapy or have the dose increased.  In some 
cases, patients will undergo re-induction therapy.  Patients experiencing immune 
reconstitution inflammatory syndrome (IRIS) can also have antifungal or HIV medications 
changed or stopped.  Sometimes IRIS is treated with corticosteroids.  Cases of relapse can be 
due to factors such as antifungal drug resistance, declining immune status that results in 
increasing fungal burden, or inconsistent use of antifungal therapy or HIV HAART therapy.  
Patients who fail initial therapy indicated by persistence of disease or drug-related toxicity 
(2b) will likely undergo a change in antifungal treatment; either in dose, the drug itself, or 
with regard to other contraindicated drugs such as corticosteroids.  The patients are at risk for 
death at any point during follow-up (Figure 3.1).  
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Data Analysis 
 
Specific Aim 1.   How do the following three groups with cryptococcosis differ with respect 
to clinical presentation and management:  HIV-positive, transplant recipients, and HIV-
negative/non-transplant patients? 
 
Exposure definitions 
 Clinical presentation variables used for comparison included demographics, 
symptoms and duration of symptoms of cryptococcosis, diagnostic tools used for diagnosis, 
and underlying conditions and possible risk factors of disease (Table 3.2).   
 Demographics – Gender, race/ethnicity, and age at time of first diagnosis of 
cryptococcosis (at DUMC) were collected.   As this is the first time this study cohort 
will be presented in the literature, demographics showing patient composition are 
valuable to readers.  
 Immune status – HIV, transplant recipients, and HIV-negative/non-transplant patients 
(3 general categories); we know from prior research that baseline immune status is 
associated with treatment exposure, treatment failure, and mortality.   
 Disease severity and disease-related morbidity – Cryptococcosis can exist in mild-to-
moderate or severe forms.  For this study, severe and non-severe categories were 
created to simplify baseline cryptococcosis severity.   Based on the IDSA Guidelines 
[1], all patients that would receive induction therapy with amphotericin B (CNS 
disease, or treat as CNS disease) were considered severe cases; non-severe cases 
would be non-CNS cryptococcosis where fluconazole therapy for primary treatment 
 29 
is recommended as sufficient.  Clinical diagnostics, such as serum and CSF antigen, 
CSF culture, and radiographic tests will likely contribute to what treatment patients 
will receive.  These clinical and microbiological results can also be indicators of 
future treatment failure or mortality.  Because they are associated with treatment 
exposure and patient treatment success and mortality, the following are possible 
confounders and may need to be adjusted for in subsequent analyses.   
 
Outcome definitions 
Clinical management and patient outcomes during follow-up were abstracted from 
patient charts.  HAART during and after treatment for cryptococcosis, including regimen and 
start and stop dates were recorded when available.  It was noted whether HAART was 
stopped during antifungal induction treatment and if so, when it was re-started (if at all).  
Similarly, trends of immunosuppressive medications for HIV-negative patients were 
examined, including dose at the time of cryptococcosis diagnosis and any changes to dose 
during antifungal treatment.   
Management of elevated intracranial pressures using serial LPs, ventricular shunting, 
lumbar drain, and/or pharmacological therapy was recorded.   
The diagnosis of immune reconstitution syndrome (IRIS) can be complex.  We 
defined it as new or worsening clinical or radiographic manifestations consistent with an 
inflammatory process such as contrast enhancing lesions on imaging studies (CT/MRI), CSF 
pleocytosis >5WBC, increased ICP, histopathology showing granulomatous lesions, and/or 
unexplained hypocalcaemia.  These symptoms must have occurred during the receipt of 
appropriate therapy and could not be explained by newly acquired infection. Also, there had 
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to be negative results for cultures or stable/reduced biomarkers for the initial fungal pathogen 
during diagnostic work-up for the inflammatory process.   
   
Analysis Plan 
Objective 1: Examine the changing populations for acquiring Cryptococcus (HIV positive, 
transplant recipients, HIV-negative/non-transplant) 
Variables were examined using descriptive statistics and stratified based on the three 
groups and/or severity of cryptococcosis as needed.  Where appropriate, the Student’s t-test 
was used to test the difference of two means and the Kruskal-Wallis test was used for the 
difference between medians for non-parametric continuous data.  Chi-square (Χ2) tests were 
used to examine differences between categorical frequency distributions.  The statistical 
significance level of alpha (α) equal to 0.05 was used for each two-tailed test performed, thus 
a “significant” result refers to a p-value <0.05.    
 
Objective 2:  Summarize temporal trends in diagnosis and amphotericin B formulations as 
initial therapy 
 Graph the percentage of patients who received amphotericin B deoxycholate and lipid 
formulations for initial therapy each year.  Examine any notable trends in use between these 
two regimens over time. 
 
Objective 3: Describe and assess differences and similarities of underlying three groups with 
respect to initial presentation, diagnostics and approaches to clinical management 
We will report prevalence and type of immunosuppression in the three groups—
HAART exposure in HIV-infected patients, corticosteroid use and immunosuppressive 
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agents among transplant and HIV-negative/non-transplant, as well as prevalence of 
patients appearing “immunocompetent.” 
 
Specific Aim 2.   How does initial antifungal therapy for cryptococcosis influence patient 
outcomes of persistence of infection, attributable mortality and overall mortality? 
 
Exposure definitions 
Initial therapy - antifungal therapy regimen based on criteria provided in Tables 2.1 and 2.2.   
Each patient was checked to see if they follow the 2010 IDSA guidelines for the 
treatment of cryptococcosis.  Appropriate initial treatment would be amphotericin B for 
severe disease and fluconazole for non-severe disease.  Induction therapy refers to the entire 
period of initial therapy, not the initial antifungal drug that was used.  
 
Treatment dose – the patient was given the appropriate dose of initial antifungal therapy.   
This study exposure is based on mg/kg units calculated using the daily dose of 
antifungal therapy given to the patient divided by the patient’s measured weight in kg at the 
closest date to cryptococcosis diagnosis.  For example, if 0.7-1.0 mg/kg/day is the 
recommended dose of amphotericin B for a patient and the patient weighs 50kg, then 35 - 
50mg, is an acceptable range of antifungal doses.  To account for initial dosing adjustments 
that can occur in the first few days of induction, the averaged dose of continuous antifungal 
therapy (no change of drug) was used to define acceptable dosing.  Acceptable dosing was 
defined as follows:  0.7-1.0mg/kg/day amphotericin B deoxycholate (AmpBd), 3-6mg/kg/day 
liposomal AmpB (L-AmpB), 4-6mg/kg/day AmpB lipid complex (ABLC), and ≥400mg/day 
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fluconazole.  Rounding to the nearest tenth for AmpBd and the nearest integer for AmpB 
lipid products were used to categorize appropriate dosing.   
 
Flucytosine-containing regimens – flucytosine was given as a combination regimen with 
primary initial amphotericin B therapy among patients with severe disease (1=yes, 0=no). 
Secondary data analysis will examine relative differences between 0 – 7 days and >7 days of 
flucytosine in combination with initial therapy.  Unique to this exposure variable, we 
hypothesized that flucytosine is more frequently paired with amphotericin B deoxycholate 
than other polyene formulations, so it was listed as a possible confounding factor (Figure 
3.3). 
  
Outcome Definitions:   
Persistent cryptococcosis, two weeks (severe disease only):  Positive cultures (CSF, blood, 
pulmonary sites, other) two weeks (14 days) after starting therapy.  The patient had to have 
survived two weeks to be eligible for this outcome because at least two weeks of induction 
therapy is recommended in this group.  We acknowledge that the IDSA Guidelines 
recommend that HIV-negative, non-transplant patients receive a minimum of four weeks of 
treatment (Table 2.2), but due to limited sample size and interest in whether or not the 
presence of disease is evident after two weeks of antifungal therapy in this group, we 
included this subgroup in this outcome.  Deaths among this patient group within two weeks 
were considered persistent infection as a sensitivity analysis. 
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Persistent cryptococcosis, four weeks (severe and non-severe disease):  Positive cultures 
(CSF, blood, pulmonary sites, other) four weeks after starting therapy and/or the positive 
indication of the presence of symptoms (headache, photophobia, fever, etc.) four weeks (30 
days) since starting primary therapy. The patient had to have survived four weeks to be 
eligible for this outcome.  Deaths among this patient group in this time period were 
considered persistent infection as a sensitivity analysis. 
Because data were observational, measures for indicating persistent infection were 
not taken at exactly two weeks and four weeks to test for positive culture, antigen testing, 
and/or infection-related symptoms.  Acceptable values were used if they did not overlap with 
the preceding measurement (e.g. a baseline culture could not be used for a two week test 
result), and did not extend beyond the designated time point (e.g. a measure at 3 weeks 
would not be counted as a week 2 measure, but instead a 4 week measure if there was not an 
observation at 4 weeks).  Persistence measures for two weeks had to have occurred ≥1 week 
of therapy.  Measures beyond the final time point (4 weeks, 30 days) were accepted for that 
final time point if within 90 days since starting therapy. 
 
Cryptococcal-attributable mortality: A determination made by a panel of experts at DUMC.  
Death was attributable to disease if at the time of expiration, patients experienced conditions 
directly related to cryptococcal disease, such as: increased central nervous system (CNS) 
pressure, persistence or relapse of infection, while receiving initial induction treatment or due 
to organ failure during treatment for cryptococcosis.   
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All-cause mortality through one year:  In order to assess one-year mortality risk for all 
patients, we obtained data on survival and mortality up to one year after their date of 
cryptococcosis diagnosis from the Duke Data Support Repository (DSR), which uses the 
Social Security Administration death index, the Tumor Registry and The Duke Information 
System for Cardiovascular Care death data to report mortality status.   
 
Secondary outcomes:  frequency of re-induction(s) with amphotericin B, IRIS and renal 
toxicity during initial therapy, receipt of ≥7 days of flucytosine compared to receipt of 0 – 7 
days of flucytosine (severe disease), and the changing initial therapy (interrupted therapy).   
  
 Re-induction: Patient had to have finished initial induction therapy for at least three 
days or have been placed on consolidation or maintenance therapy, then placed back on 
amphotericin B as part of re-induction status. 
  
 IRIS: The definition for IRIS for this study, adapted from Singh and Perfect [94] was 
the following:  A clinical or radiographic manifestations consistent with an inflammatory 
process such as contrast enhancing lesions on imaging studies (CT/MRI) along with (a) and 
(b) and at least one of (c) through (f): 
a) Symptoms occurred during receipt of appropriate therapy and could not be explained 
by newly acquired infection 
b) Negative results for cultures or stable/reduced biomarkers for the initial fungal 
pathogen during diagnostic work-up for the inflammatory process 
c) CSF pleocytosis >5 WBC/mm3 
d) Increased intracranial pressure (ICP) 
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e) Histopathology showing granulomatous lesions 
f) Unexplained hypercalcemia 
 
 Renal toxicity: Creatinine values measured closest to day 0 and day 14 of treatment 
for patients with severe disease who received induction therapy with amphotericin B were 
used to determine renal toxicity.  Defined as a >50% decrease in Glomeruler Filtration Rate 
(GFR), also known as estimated creatinine clearance, during initial induction treatment.  
GFR was calculated using the CKD-EPI (Chronic Kidney Disease Epidemiology 
Collaboration) formula [99]. 
 
Analysis Plan 
Objective 1:  Determine the association of aspects of initial treatment on poor patient 
outcomes that include the risk of persistent infection and rates mortality due to 
cryptococcosis and overall 1-year mortality.  
1. Estimate the effect of initial antifungal treatment type on persistence and mortality 
2. Estimate the effect of initial treatment dosing on persistence and mortality 
3. Estimate the effect of flucytosine exposure among patients with severe cryptococcosis 
disease on persistence and mortality 
a. Estimate the effect of ≤ 7 days or >7 days of flucytosine on the rate patient 
mortality and  the risk of persistence among patients surviving at least 14 days 
from the time starting antifungal therapy  
4. Assess other strong predictors for the above outcomes in (1) (Table 3.2, Figures3. 2 
and 3.3) 
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Follow-up begins on the first day of starting treatment.  Because the follow-up 
periods were short (two weeks and four weeks) for persistence outcomes, thus minimizing 
competing risks, binomial regression was used to estimate the risk ratios (relative risk [RR]) 
for the separate (main) effects of receipt of recommended initial treatment type, 
recommended initial treatment dose and flucytosine combination treatment exposure (severe 
disease only) on the dichotomized outcomes of persistence at two weeks (severe disease 
only) and persistence at four weeks, adjusting for important covariates (Figures 3.2 and 3.3).  
Patients who were untreated with anti-cryptococcal therapy (n=3) were excluded from this 
analysis. 
To evaluate confounding we will assess the bivariate associations between all 
covariates and main exposures and outcomes.  Minimum adjustment sets will be determined 
using the Directed Acyclic Graph (DAG) program (v0.21) [100].  Should minimum 
adjustment sets exceed what our limited study size could operably model, the minimum 
adjustment sets for each of our three chosen exposures (with slight variation), based on 
previous studies that predicted poor outcomes [13,15,16,17,18,19,20,21], variables associated 
with severe underlying condition and high fungal burden from our minimal adjustment sets 
will be prioritized and we will proceed with  multivariate adjustment using a change-in-
estimate approach with a 10% cut-off criterion [101]; eliminating variables chosen by the 
DAG program that did not confound the association of effect estimates between the main 
exposures and outcomes.  Effect measure modification by confounding variables will be 
examined through the inclusion of interaction terms in the models and using the spreadsheet 
by Andersson et al. (2005) to determine the relative excess risk due to interaction 
(RERI)[102].  Corresponding 95% CIs will be estimated to measure the precision for each 
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estimate of exposure and outcome association.  Changes in the precision of estimates will be 
examined with the confidence limit ratio (CLR).   
Binomial regression will be used to estimate the risk ratio (RR) of the association 
between treatment exposures and these outcomes.  Cox proportional hazards models will be 
used to estimate hazard ratios (HR) for the association between treatment exposures and 
mortality outcomes.  Assessment of the proportional hazards assumption (PHA) will be 
performed using graphical methods (ln – ln survival plot) and by adding an interaction 
between exposure and (log) time.  
Abstraction forms were entered into Microsoft Office Access (2007) and data 
analyses were performed using SAS v9.2 (SAS Institute, Cary, North Carolina). Investigators 
recorded all information on a standardized abstraction form developed in collaboration with 
epidemiologists and clinicians.   
 
Objective 2.   Report the frequency of secondary outcomes of Immune Reconstitution 
Inflammatory Syndrome (IRIS), renal toxicity measured by at least a 50% decline in 
Glomerular Filtration Rate (GFR), re-induction of antifungal therapy, and changing 
antifungal therapy during initial induction.   
 Understanding the distribution frequencies of these secondary outcomes is important 
in understanding clinical management strategies and making future recommendations.  
Prevalence of these events will be assessed and patterns of changing therapy described in the 
context of the three groups.     
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Strengths and limitations of methods 
 
Despite its limitations, this study represents an important insight into how the 
cryptococcosis patient is being managed and what the outcomes have been.  To our 
knowledge it is the largest single-center cryptococcosis cohort and provides in-depth 
information on a heterogeneous group of patients experiencing disease (HIV-infected, 
transplant recipients and other HIV-negative patients).  The importance of trends within and 
between these three groups will help to inform clinicians regarding at-risk populations, and 
how these groups may be shifting as HAART among HIV-infected patients expands and 
immunosuppression places other groups at a higher potential risk for cryptococcosis.  With 
careful retrospective chart review we were able to capture the intricacies of patient treatment, 
which included:  halting corticosteroid use, dose changes, switching of initial antifungal 
therapy, and duration of therapy.  Future studies combining our cohort with additional patient 
groups from other institutions would provide beneficial robustness for treatment 
effectiveness analyses and encourage this group cooperation.   
This review was limited to a single tertiary care center and teaching hospital.  Our 
medical center averaged nearly 15 cases of cryptococcosis per year and this likely reflects 
both an endemic exposure to this yeast in the environment within the Southeastern USA and 
an enriched population of immunosuppressed individuals due to our hospital’s care patterns.  
The actual number of cases seen in a particular medical center certainly varies within the 
U.S.  Furthermore, using hospital records favors cases with severe disease and could result in 
selection bias against asymptomatic disease.  Determining the total population-at-risk was 
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not estimable in this study and the underlying source population and referral patterns could 
shift over time.   
Retrospective chart review has the potential for incomplete or incorrect information 
capture due to loss of paper documentation or lack of entry in electronic medical record.  We 
used both sources to ensure data was as complete as possible and discrepancies were 
minimized.  Erroneous self-report of symptoms or symptom duration was a possibility, but 
this is a limitation of many observational clinical studies.  Despite our careful abstraction 
process, missing or incomplete data could lead to bias in categorization of symptoms or 
derived outcome definitions, such as IRIS.  Lumbar puncture opening pressure data was 
inconsistent and missing in about 40% of initial procedures.  However, knowing how 
infrequent lumbar punctures are performed is an informative fact of real-world clinical 
practice.  Other measures may be needed to identify elevated intracranial pressures and 
clinically manage patients with severe cryptococcosis. 
Being a rare disease, limited numbers of cases prevented robust statistical analyses.  
Importantly, much of the clinical attention over the last two decades has centered around two 
groups (HIV-infected and transplant recipients).  There has been less focus on treatment of 
HIV-negative/non-transplant patients and yet this group accounts for over one-third of the 
total cases.  
In order to obtain a reportable picture of various outcomes, we created definitions of 
severe versus non-severe, persistence of infection (two and four weeks), attributable 
mortality, and we used the IDSA guidelines to define “appropriate” therapy.  Others could 
definitely choose these definitions, but one fact clearly remains—the overall mortality rate in 
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severe cryptococcosis is almost 25% within one year and in our opinion that rate remains too 
high. 
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Tables  
 
Table 3.1.  Antifungal treatment response definitions in patients with cryptococcal disease.  
Adapted from Seagal et al, 2008 [98]. 
Success  
Complete  
(or partial) 
     
     
Survival and resolution (or improvement) of attributable signs and 
symptoms of disease; 
AND documented clearance of pathogen from CSF, blood, other sites; 
AND improvement or stabilization of positive radiologic findings  
Failure  
Stable 
 
 
Progression 
 
 
Death 
Survival and minor or no improvement in attributable signs and 
symptoms of disease;  
AND persistently positive CSF or other cultured specimens 
Worsening of clinical signs or symptoms; 
AND persistently positive CSF or other cultured specimens;  
OR new sites of disease or worsening of preexisting radiologic lesions; 
Death during the period of evaluation
a
 
a
 Period of evaluation subjective to the research study and will be death ≤1 year from diagnosis for 
our investigation. 
 
 
  
4
2
 
Table 3.2.  Binary variable specification used for cohort description and analysis.  Unless specified, Yes = 1 and No = 0. Table is 
continued on following two pages. 
Category Variable list
a
 Brief Description 
Exposures   
 Initial therapy Patient received appropriate initial therapy disease given their diagnosis of severe 
or non-severe cryptococcosis (1=No, 0=Yes) 
 Dose of initial therapy Patient received a recommended dose of  initial therapy (1=No, 0=Yes) 
 Flucytosine  Patient received flucytosine in combination with amphotericin B for their initial 
treatment regimen (severe disease only).  Categories used for secondary analysis 
were: 0 – 7 and >7 days of flucytosine among those who survived ≥14 days from 
the start of initial therapy. 
Outcomes   
 Persistent cryptococcosis (1) Positive cultures 2 weeks after starting initial therapy (severe disease only); (2) 
Positive cultures 4 weeks after starting initial therapy, OR positive indication of the 
presence of crypto-related symptoms 4 weeks since starting primary therapy.  Both 
outcomes were conditional on survival ≥14 days from the start of initial therapy.  
 Attributable mortality Determined by a panel of experts that death was attributable to conditions that were 
directly related to cryptococcal disease 
 Overall mortality Timing of death within one year of follow-up with patients alive or lost to follow-
up by the end of one year as censored subjects  
Demographics   
 Male gender Patient was male  
 Black Race Patient was African American  
 Age <44 years (0) or  ≥44 years (1); median age as a cut point  
Underlying 
Condition
b 
 
  
 HIV positive Patient had HIV at the time of cryptococcosis diagnosis 
 Organ transplant recipient Patient received organ transplant before cryptococcosis diagnosis 
 HIV-negative, non-transplant Patient was negative for HIV and had not received a solid organ transplant 
 Renal insufficiency  Evidence of renal failure on admission 
 Liver insufficiency  Evidence of liver failure on admission 
 Hematologic malignancy Underlying hematologic malignancy at the time of cryptococcosis diagnosis 
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Category Variable list
a
 Brief Description 
Baseline Disease   
 Severe disease Patients with disease where induction therapy with amphotericin B is 
recommended by IDSA Guidelines (CNS disease, or treat as CNS disease) [1]; 
non-severe cases were non-CNS disease where fluconazole therapy for primary 
treatment is recommended 
 Positive CNS culture Patient had positive fungal culture from CSF 
 Positive blood culture Patient had positive fungal culture from blood 
 Positive pulmonary culture Patient had positive fungal culture from lung biopsy or bronchoalveolar lavage 
 Other histological evidence Other histological test positive for Cryptococcus 
Symptoms    
 No symptoms Patient reported no disease-attributable symptoms 
 Altered mental status Yes/No 
 Headache  Yes/No 
 Cough  Yes/No 
 Shortness of breath Yes/No 
 Night sweats Yes/No 
 Fever Yes/No 
 Nausea Yes/No 
 Vomiting Yes/No 
 Seizures Yes/No 
Initial LP
c
   
 CSF CRAG
d
 titer ≥1:1024 High was defined as  ≥1:1024 
 Low CSF:serum glucose ratio CSF:serum glucose ratio was <0.6 
 Low CSF glucose CSF glucose ≤40mg/dL 
 High CSF protein CSF protein ≥45mg/dL 
 High nucleated cells Nucleated cells >20cells/mm
3
 
 High LP OP
e
 OP ≥20cm H2O 
 Positive India Ink  Patient had a positive India ink stain 
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Category Variable list
a
 Brief Description 
Other   
 High serum CRAG titer Serum CRAG titer ≥1:1024 
 Corticosteroid exposure  Patient on corticosteroid therapy at time of cryptococcosis diagnosis 
 Calcineurin inhibitor Patient taking calcineurin inhibitor  
 Mycophenolate mofetil Patient taking mycophenolate mofetil  
 Azathioprine Patient taking azathioprine  
 Methotrexate Patient taking methotrexate  
 Monoclonal antibodies Patient taking monoclonal antibodies 
 Sirolimus Patient taking sirolimus  
 HAART  HIV-infected patient reported prior or current exposure to HAART 
a
 Unless unavailable and where applicable, all information was gathered from the procedure or chart entry closest to cryptococcosis diagnosis date.   
b
 Since HIV positive, transplant recipients and HIV-negative/non-transplant groups were exclusive categories, dummy variables indicating the 
three groups were used for multivariate models.   
c
 LP = Lumbar puncture; first measured value for each patient 
d
 CRAG = Cryptococcal antigen 
e
 OP = Opening pressure 
 45 
Figures 
 
Figure 3.1.  Conceptual model showing timing of patient cohort conditions and events.  All 
patients enter the study at the time of diagnosis and are followed until death, lost to follow-up 
or until the end of the study period (October 31
st
, 2009).  
1. Patient is diagnosed 
with cryptococcosis  
1a. Died 
before 
therapy 
 
2. Antifungal 
treatment 
started 
3. Patient 
cured or 
suppressed 
with 
maintenance 
therapy 
4. Patient 
dies or lost 
to follow-up 
2a. Patient 
dies while on 
therapy 
Change in 
antifungal 
therapy 
3a. Relapse of 
cryptococcosis or 
IRIS 
3b.Patient dies 
2c. Patient dies 
2b. Fails 
therapy due 
to treatment 
toxicity or 
persistence 
of infection 
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Figure 3.2. Simplified causal diagram for specific aim 2: initial treatment and dose of initial 
treatment.  Covariates listed were determined as the minimum adjustment set for models by 
the DAG program by Knüppel [100]. 
 
 
 
 
Main Exposures: 
 Appropriate initial therapy 
regimen as recommended 
by IDSA Guidelines 
  
Main Outcomes: 
 Persistence of disease 
 Attributable mortality 
 Overall mortality 
Main Confounders or Effect Modifiers:   
 Severe disease 
 Underlying condition (HIV, transplant status) 
 Hematologic malignancy 
 Positive blood culture  
 Positive CNS culture 
 High CSF CRAG titer (≥1:1024) 
Other Confounders or Effect Modifiers:   
 Positive India Ink 
 High serum CRAG titer (≥1:1024) 
 Positive biopsy or BAL 
 Presence of symptoms 
 Liver or renal failure 
 Corticosteroid therapy 
 Seizures  
 Duration of symptoms ≥14 days prior to presentation 
 Unmeasured variables, such as radiographic findings 
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Figure 3.3. Simplified causal diagram for specific aim 2: flucytosine exposure (severe disease 
only). Covariates listed were determined as the minimum adjustment set for models by the 
DAG program by Knüppel [100]. 
  
Main Exposures: 
 Flucytosine combination 
therapy used (yes/no) 
 ≤7 vs. >7 days of flucytosine  
Main Outcomes: 
 Persistence of disease 
 Attributable mortality 
 Overall mortality 
Main Confounders or Effect Modifiers:   
 Hematologic malignancy 
 Positive blood culture  
 Positive CNS culture  
 Underlying condition (HIV, transplant status) 
 High CSF CRAG titer (≥1:1024) 
 Receipt of AmpBd as initial primary therapy 
Other Confounders or Effect Modifiers:   
 Corticosteroid therapy 
 High serum CRAG titer (≥1:1024) 
 Positive India ink 
 Seizures  
 Liver or renal failure 
 Duration of symptoms ≥14 days prior to presentation 
 Presence of symptoms 
 Unmeasured variables 
  
CHAPTER IV.  COMPARISON AND TEMPORAL TRENDS OF THREE GROUPS 
WITH CRYPTOCOCCOSIS:  HIV-INFECTED, SOLID ORGAN TRANSPLANT 
AND HIV-NEGATIVE/NON-TRANSPLANT 
 
Overview 
  
 The Infectious Disease Society of America (IDSA) 2010 Clinical Practice Guidelines 
for the management of cryptococcosis outlined three key populations at risk of disease:  (1) 
HIV-infected, (2) transplant recipient, and (3) HIV-negative/non-transplant.  However, direct 
comparisons of management, severity and outcomes of these groups have not been 
conducted.  Annual changes in frequency of cryptococcosis diagnoses, cryptococcosis-
attributable mortality and mortality were captured.  Differences examined between severe 
and non-severe disease within the context of the three groups included:  demographics, 
symptoms, microbiology, clinical management and treatment.  An average of nearly 15 
patients per year presented at Duke University Medical Center (DUMC) with cryptococcosis. 
Out of 207 study patients, 86 (42%) were HIV-positive, 42 (20%) were transplant recipients, 
and 79 (38%) were HIV-negative/non-transplant.  HIV-infected individuals had profound 
CD4 lymphocytopenia and a majority had elevated intracranial pressure.  Transplant 
recipients commonly (38%) had renal dysfunction.  Nearly one-quarter (24%) had their 
immunosuppressive regimens stopped or changed.  The HIV-negative/non-transplant 
population reported longer duration of symptoms than HIV-positive or transplant recipients 
and 28% (22/79) had liver insufficiency or underlying hematological malignancies.  HIV-
 49 
positive and HIV-negative/non-transplant patients accounted for 89% of severe disease 
cryptococcosis-attributable deaths and 86% of all-cause mortality.  In this single-center 
study, the frequency of cryptococcosis did not change in the last two decades, although the 
underlying case mix shifted (fewer HIV-positive cases, stable transplant cases, more cases 
with neither). Cryptococcosis had a relatively uniform and informed treatment strategy, but 
disease-attributable mortality was still common. 
 
Introduction  
 
Cryptococcus neoformans is an invasive mycoses that can cause meningoencephalitis, 
particularly among those who are immunocompromised, but in some cases 
immunocompetent individuals [3].  The 2010 IDSA Cryptococcal Guidelines defined three 
distinct risk groups for induction treatment of cryptococcosis [1,3]:  (1) HIV-positive; (2) 
transplant recipients; and (3) a heterogeneous group with neither of these conditions (i.e., 
HIV-negative/non-transplant). A major component of this review was to describe outcomes 
of recent management of these three groups.  During this study, four important factors were 
in play that justified our decision to use the broad 14-year study period in order to maximize 
cohort size.  First, HAART became readily prescribed in 1996 with supportive evidence of 
the superiority of combination antiretroviral therapy over monotherapy in reducing AIDS 
morbidity and mortality [103] .  Second, lipid products of amphotericin B, for patients with 
renal impairment or unacceptable toxicity that prevents the use of conventional amphotericin 
B,  were in use since their initial FDA approval in November, 1995 [104].  Third, in 2000 the 
original IDSA Guidelines were published as a standard of treatment [15].  Fourth, there was 
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an active Infectious Disease group at our institution with a particular interest in the 
pathogenesis and treatment of cryptococcosis.   
HIV-positive populations with cryptococcosis have been the most widely studied 
group over the last two decades [5,13,41,42,47,78,105,106,107,108,109,110,111] and have 
received greater attention recently due to the recognition that cryptococcosis incidence in this 
group remains high and paralleled with the AIDS epidemic in sub-Saharan Africa [23].  
Starting in the 1960 – 1980’s, use of immunosuppressive medications to treat severe diseases 
or for solid organ transplantation has increased the pool of patients susceptible to 
Cryptococcus and, in the late 1990’s Cryptococcus gattii emerged in Vancouver Island, 
British Columbia, Canada, resulting in an outbreak of infections in both immunosuppressed 
and immunocompetent hosts [38,39].  Though clinical isolates were not typed in this study, 
serotype A (C.neoformans var. grubii) predominates this region [112]; C.gattii is rare in the 
Southeastern U.S. with only one identified clinical case in an immunocompromised adult 
[40].  The HIV-negative cryptococcosis patient group had been excluded from clinical 
review for several decades but has gained more attention recently [21,45,62,68,69,70].  
Cryptococcal patients who are HIV-negative, particularly those who have few or no 
underlying risk factors (i.e., “apparently immunocompetent”), may experience more of a 
delay in time to presentation and diagnosis than HIV-positive or transplant recipient patients 
[21].  In particular, recent evidence from a study showed that HIV-negative, non-
immunosuppressed cryptococcal meningitis patients suffered higher mortality rates than 
HIV-positive patients [62].     
Due to its rare occurrence, prospective observational studies of this disease are 
logistically problematic.  Interventional approaches have historically been based on expert 
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opinion and outdated and retrospective cohort studies, with few representing HIV-negative 
populations and comparatively developed countries [19,21,22,48].  In this relatively large, 
retrospective single-center study, our goal was to provide an in-depth look at how 
cryptococcosis was managed clinically in the HIV-positive, transplant recipient and HIV-
negative/non-transplant patient groups in order to improve our understanding of this disease.   
 
Methods  
 
Objectives 
The goals of this study were to describe trends in cryptococcosis symptoms, 
diagnosis, treatment and mortality through a 14-year study period (1996–2009) within the 
context of the three groups defined by the IDSA Guidelines.   
 
Participants 
We identified all consecutive adult patients (≥18 years old) discharged from DUMC 
with International Classification of Diseases, 9th Revision (ICD-9) diagnosis codes of 
cryptococcosis (117.5), and cryptococcal meningitis (321.0) between January 1, 1996 and 
October 31, 2009 through electronic medical records.  Eligible subjects had confirmed 
cryptococcal disease and a sufficient medical record (electronic and/or paper chart) available 
for review.  A cryptococcosis case was confirmed by having ≥1 of the following:  positive 
cerebral-spinal fluid (CSF) cryptococcal antigen (CRAG) or fungal culture, direct 
histological examination of tissue or fluid with characteristic yeast forms of Cryptococcus, 
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positive serum cryptococcal antigen test with a consistent disease process or positive culture 
from blood or pulmonary sites.   
 
Description of Investigations 
Demographics, presenting symptoms (including duration), and underlying conditions 
at the time of diagnosis were collected.  Clinical differences examined included:  presentation 
and duration of symptoms, microbiological evidence of cryptococcal disease, and initial 
antifungal treatment.  Follow-up visit information relevant to cryptococcosis (laboratory 
testing, clinic visits, and readmission) was also captured.  Patients were followed from the 
date of diagnosis and/or admission until loss-to-follow-up, death, or until the end of the study 
period.  In order to assess one-year mortality prevalence for all patients, we obtained data on 
survival and mortality up to one year after their date of cryptococcosis diagnosis from the 
Duke Data Support Repository (DSR), which uses the Social Security Administration death 
index, the Tumor Registry and The Duke Information System for Cardiovascular Care death 
data to report mortality status.  Investigators recorded all information on a standardized 
abstraction form developed in collaboration with epidemiologists and clinicians.   
We report on annual changes in frequency of cryptococcosis diagnoses, treatment, 
and outcomes including: overall mortality through one year, deaths attributable to 
cryptococcosis, and occurrence of immune reconstitution inflammatory syndrome (IRIS).  
Defined and determined by a panel of experts at DUMC, death was attributable if patients 
experienced conditions directly related to cryptococcal disease, such as: increased central 
nervous system (CNS) pressure, persistence or relapse of infection, while receiving initial 
induction treatment or due to organ failure during treatment for cryptococcosis.  The criteria 
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used to identify IRIS, adapted from Singh and Perfect (2007), included clinical or 
radiographic manifestations consistent with an inflammatory process, such as contrast 
enhancing lesions on imaging studies (CT/MRI), combined with symptoms that occurred 
during receipt of appropriate therapy and could not be explained by newly acquired infection, 
and at least one of the following:  (1) negative results for cultures or stable/reduced 
biomarkers for the initial fungal pathogen during diagnostic work-up for the inflammatory 
process, (2) CSF pleocytosis >5 WBC/mm3, (3) Increased ICP, (4) histopathology showing 
granulomatous lesions, or (5) unexplained hypercalcemia [94].  
Central nervous system (CNS), pulmonary and ‘other’ cryptococcosis patients were 
collapsed into two categories based on specific indicators described in the 2010 IDSA 
Treatment Guidelines [1]: severe disease (all patients with evidence of central nervous 
system (CNS) involvement, or those with cryptococcemia or dissemination with evidence of 
high fungal burden based on CRAG ≥1:512) or non-severe disease.  
 
Ethics 
This study was approved by both the Duke University Medical Institutional Review 
Board (IRB) and the University of North Carolina at Chapel Hill Biomedical IRB. Both 
named IRBs waived the need for informed consent for this study. This research met criteria 
for a waiver of informed consent according to Title 45, Code of Federal Regulations (CFR) 
Part 46.116(d).  
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Statistical Methods 
All data was entered into Microsoft Office Access (2007) and analyses were 
performed using SAS v9.2 (SAS Institute, Cary, NC).  Variables were examined using 
descriptive statistics and stratified based on the three groups and/or severity of 
cryptococcosis as needed.  Where appropriate, the Student’s t-test was used to test the 
difference of two means and the Kruskal-Wallis test was used for the difference between 
medians for non-parametric continuous data.  Chi-square (Χ2) tests were used to examine 
differences between categorical frequency distributions.  The statistical significance level of 
alpha (α) equal to 0.05 was used for each two-tailed test performed, thus a “significant” result 
refers to a p-value <0.05.    
 
Results  
 
There were 223 study patients identified; 16 were excluded due to the following 
reasons:  unable to locate chart (n=1), transferred out of care prior to diagnostic test results 
and did not receive treatment at DUMC (n=4), patient <18 years (n=1), and the patient did 
not have verified cryptococcal disease (n=10).  A total of 207 patients were used for analysis.  
The majority of cases were CNS disease (61%), followed by pulmonary (34%) and other 
sites (Table 4.1).  Consistent across the three clinical groups, nearly two-thirds of the cohort 
were male (65%) and African Americans were more prevalent among HIV-positive patients 
than the other two groups (Table 4.1).  HIV-positive patients were significantly younger than 
the other two groups.  
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Overall annual case frequencies of cryptococcosis did not significantly change over 
time (Figure 4.1).  During the study period, the number of transplant patients per year 
averaged three (range, 0–5 cases/yr.).The frequency of HIV-infected cases averaged six 
annually (range, 2–12 cases/yr.).  Among HIV-negative, non-transplant cases there was a 
slight increasing trend with time; the annual average number of cases was six (range, 3–9 
cases/yr.). Although the total cases have remained relatively steady (~15/yr.), there appeared 
to be a shift to a decreasing proportion of HIV-positive patients with a concomitant increase 
in HIV-negative cases. HIV-positive patients accounted for half of all cases in the first seven 
years of this study then fell to less than one-third in the latter seven years. 
 
Within-group observations  
Within the HIV-positive patient group (n=86), 74 (86%) had CNS disease, 9 (11%) 
had pulmonary cryptococcosis and three patients had another form of cryptococcosis (Table 
4.1).  Twenty-seven (31%) patients were newly identified as positive for HIV infection 
during their hospital admission for cryptococcosis.  CD4 counts were available for 62 (72%) 
patients during hospitalization (median, 22 cells/µL; range: 1-300 cells/µL).  Forty-two 
percent of HIV-positive patients with severe (n=31) and non-severe (n=5) cryptococcosis 
reported current or previous exposure to HAART therapy, but management compliance was 
heterogeneous.  Prevalence of reported HAART exposure did not differ significantly 
comparing earlier (1996 – 2002) and later cases (2003 – 2009).  During admission 18 patients 
(21%) continued their known HAART therapy, four patients (5%) changed to another 
regimen, six patients (7%) continued their current therapy but changed their regimen at the 
time of discharge and six patients had their therapy held on admission.  Seventeen patients 
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(20%) had no confirmed previous exposure to HAART; eight died with cryptococcal disease-
related deaths.  Thirty-five patients (41%) were started newly on HAART therapy at the time 
of or after discharge.  The median time-to-start of HAART therapy was 67 days after the start 
of initia therapy.  
Among transplant recipients (n=42), 18 (43%) had CNS disease (severe) and 24 
(57%) had pulmonary disease (non-severe; Table 4.1). The majority of transplants were renal 
(n=17; 4 included pancreas) followed by cardiac (n=11) and pulmonary (n=9).  The median 
time from transplant to diagnosis of cryptococcosis (n=41) was 26 months (Inter-Quartile 
Range [IQR]: 10–56 months).  Over one-third (n=16) of transplant recipients had renal 
insufficiency at the time of diagnosis (Table 4.2), but only two patients (11%) with severe 
disease experienced a >50% decrease in Glomerular Filtration Rate (GFR) during induction 
treatment.  Current steroid exposure at the time of cryptococcosis was high (93%), and 19 
patients (24%) had their immunosuppressive therapy stopped or changed at the time of their 
cryptococcosis diagnosis.  Of the 39 patients taking steroids prior to cryptococcosis 
diagnosis, 37 (95%) had dose information.  The median daily dose was 10mg of prednisone 
or prednisone equivalent (range: 4 – 30mg/day).  Most of these patients had been on 
extended immunosuppressive therapy.  The median duration of immunosuppression (n=39) 
was 19 months (IQR: 8 – 56 months).  
In the HIV-negative/non-transplant group (n=79), 34 (43%) had CNS disease, 38 
(48%) had pulmonary cryptococcosis and 7 (9%) had another form of cryptococcosis (Table 
4.1). There were 37 (47%) patients with no underlying malignancy or immunosuppressive 
therapy at the time of diagnosis.  Ninety percent of all cancers in the cohort were among 
HIV-negative, non-transplant patients (Table 4.2).  Of the 31 patients (39%) taking steroids 
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prior to cryptococcosis diagnosis, 24 (77%) had dose information.  The median daily dose 
was 20mg prednisone or prednisone equivalent (range: 5–267mg/day).  The median duration 
of any type of immunosuppressive therapy (N=21) was 7 months (IQR: 1 – 36 months).  
Eight patients (21%) with severe disease experienced a >50% decrease in GFR during 
induction treatment. 
 
Clinical symptoms 
There were 21 patients (10%) who were asymptomatic at the time of diagnosis (Table 
4.2).  Of the 19 with asymptomatic pulmonary disease, 10 were transplant recipients and nine 
were HIV-negative/non-transplant patients.   
Among the patients reporting symptoms (n=186), the duration of symptoms was 
unknown for 30 patients; 10 (12%) patients among those with HIV, seven (22%) of 
transplant recipients and 13 (18%) of the patients in the third group.  Excluding these 
patients, the mean length of symptoms prior to presentation was not significantly different 
between severe and non-severe disease.  The mean symptom duration was longer for the 
HIV-negative/non-transplant patients than either of the other two groups (Table 4.3).  When 
compared to this group, the difference in means was -25 days (95% Confidence Limits [CL] -
50, 1) for the HIV-positive patients and -20 days (95% CL -48, 8) for transplant recipients 
with severe disease.  The differences in means were even greater when comparing the groups 
with non-severe disease (Table 4.3).  
Patients with severe disease frequently experienced headaches, altered mental status, 
fevers, nausea and vomiting across all three groups at initial presentation (Table 4.2).  The 
prevalence of nausea and vomiting was significant between groups with them being more 
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common in HIV and transplant recipients.  Furthermore, headache was significantly more 
prevalent among HIV-positive patients (73%) and similar between the other two groups. 
Symptoms among non-severe cryptococcosis patients were similar between transplant 
recipients and HIV-negative/non-transplant groups.  However, the prevalence of 
corticosteroid exposure was significantly higher in transplant recipients (Table 4.2).   
 
Patient diagnostics 
Among patients with severe disease, patients had similar lumbar puncture (LP) 
results among all three groups (Table 4.4).  At least one opening pressure (OP) measurement 
was available for 79 (63%) patients.  Peak OP distributions were very similar between all 
three groups with a mean of 33cm H2O (SD±16cm H2O).  The proportion of HIV-positive 
patients (48%) with elevated CSF host cells (≥20 cells/mm3) was significantly less than the 
other groups, which had frequencies of 78% and 61% (Table 4.4).  The difference in 
frequencies across all three patient groups having an elevated CSF CRAG titer (≥1:1024) and 
positive India ink neared significance.  With regard to the frequency of these two CSF 
diagnostic measures, further comparison of non-HIV/non-transplant with the other two 
groups combined (differences in frequencies between HIV-positive and transplant patients 
were not significant) indeed reached the level of significance.  CSF glucose and protein 
levels were similar in all groups (~40% of all patients had hypoglycorrhachia). There was no 
significant difference between groups in regards to cryptococcemia (Table 4.4). 
Among non-severe disease patients, histological evidence of Cryptococcus was 
identified in over 60% of the two HIV-negative groups (Table 4.4).  Positive pulmonary 
cultures were identified by at least one positive culture, biopsy or broncho-alveolar lavage in 
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>50% of HIV-negative patients, whereas only 17% (n=2) of HIV-positive patients had 
documentation of pulmonary disease.  Of the 40 HIV-negative/non-transplant patients, 22 
(55%) received an LP to rule out CNS disease, which was not significant compared to the 18 
(75%) transplant recipients but was significant compared to the 11 (92%) HIV-infected 
patients who received an LP when non-severe disease was identified.   
 
Initial Treatment 
During the study period, 132 patients (64%) received amphotericin B (either 
formulation) for initial therapy.  Utilization of amphotericin B deoxycholate (AmpBd) 
decreased over time, indicating that lipid formulation amphotericin B (LFAmpB) was used 
more frequently as initial therapy in recent years (Figure 4.2).  Despite this observed trend, 
AmpBd was used as initial therapy for 80% of patients across the entire study period. 
Initial antifungal regimens are summarized in Table 4.5.  Eighty percent of patients 
with non-severe disease were given fluconazole for initial treatment; this was not 
significantly different across the three risk groups.  In the severe disease group, the frequency 
of polyene use as initial therapy was high for all three patient groups (89% of HIV-positive, 
100% of transplant, and 87% of HIV-negative/non-transplant), as was the use of flucytosine 
in combination with the polyene (78% of HIV-positive, 83% of transplant, and 72% of HIV-
negative/non-transplant).   
 
Mortality and IRIS 
Mortality attributable to cryptococcosis was 15% (n=31) and there was a total of 52 
deaths (25%) through one year of follow-up (Table 4.5).  HIV-positive and HIV-
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negative/non-transplant patients accounted for 89% of severe disease cryptococcosis-
attributable deaths and these two groups accounted for 86% of all-cause mortality.  IRIS was 
identified in seven (3%) cases and most of these cases had severe cryptococcosis.  Four out 
of the seven patients were HIV-positive but IRIS was observed in the other two groups.   
The HIV-negative/non-transplant group experienced both greater mortality 
attributable to cryptococcosis and overall mortality, since they accounted for nearly half of 
all cryptococcosis-attributable deaths (15/31) and more than half of all-cause mortality 
(29/52).  Within this group, patients who died were older at diagnosis (mean, 63 years) than 
those who did not (mean, 51 years).  However, the average age at diagnosis was not 
significantly different between survivors and those who died within either the HIV-positive 
or transplant groups.   
 
Discussion  
 
The 2010 IDSA Guidelines divided cryptococcal disease into three risk groups 
because of their different management issues in an attempt to better describe the issues 
around treatment and outcome [1].  The results from our study found notable trends and 
important clinical differences between and within these groups and uniquely describes the 
realities in the management of this disease at one institution. 
In the early parts of the 14-year study period, the highest number of cases occurred in 
the HIV-infected population and appeared to experience fewer of these infections recently, 
coinciding with the widespread use of HAART.  However, 42% of HIV-positive patients in 
this cohort had been exposed to HAART, emphasizing that despite therapies to control HIV 
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infection, cryptococcosis will continue to be an opportunistic infection in HIV-infected 
persons.   The HIV-negative/non-transplant patients appeared to offset the reduction of 
cryptococcosis seen in HIV-infected patients in more recent years.  As we continue to 
aggressively treat serious underlying diseases with immunosuppressants and the denominator 
of persons-at-risk enlarges, this group will likely increase since there is no strategy for 
prophylaxis.  There were a consistent number of cases of cryptococcosis in the transplant 
recipients over time despite the widespread use of the potentially anti-cryptococcal agents, 
the calcineurin inhibitors [56,113,114,115,116].  The steady annual prevalence  of 
cryptococcosis in this group supports the continued routine use of immunosuppressants and 
thus a persistent need for careful diagnostic surveillance for detection of early cryptococcosis 
[117].    
The differences within the groups were several.  For HIV-infected individuals, there 
was a variety of antiretroviral strategies employed during anti-cryptococcal therapy that 
reflects the lack of precise guidelines on when to initiate HAART [118].  Similar to previous 
studies, most of these patients had profound CD4 lymphocytopenia and a majority of these 
patients (76%) had elevated intracranial pressure [2,4,42,111].  The important underlying 
issues surrounding transplant recipients were immunosuppressive drugs and frequent renal 
dysfunction.  All had some form of immunosuppression but only one-quarter had their 
immunosuppressive regimens stopped or changed and the prevalence of IRIS was low.  Also, 
one-third of patients started treatment with evidence of renal dysfunction, emphasizing that 
lipid products of amphotericin B may be essential therapeutic choices in this group and that 
monitoring flucytosine levels and/or complete blood counts may be necessary to prevent 
treatment toxicity during worsening of renal dysfunction caused by polyene treatment [43].  
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Moreover, the average time from transplant to cryptococcal infection was within range of the 
17 – 28 months reported in previous studies [43,61,115,119,120].   There were two important 
findings in the HIV-negative/non-transplant group.  First, the duration of symptoms in this 
group with severe disease averaged 44 days prior to diagnosis and although not reaching 
significance from the other groups (it was significant among those with non-severe disease), 
this notable delay deserves greater attention and has been observed in a previous case series 
[68].  This delay may have contributed to the observed poorer outcome of the group.  
Another study also found a lack of significance between HIV-infected, 
immunocompromised, and immunocompetent groups, where the symptom duration averaged 
approximately 15 days [62].  It is possible that the other two groups have specialists aware of 
the risk of cryptococcosis, while in this group diagnosis gets delayed because it is not 
considered in the initial differential diagnosis. Second, 33% had liver insufficiency or 
hematological malignancies.  These are important findings as this subgroup had the highest 
mortality and both factors have been shown to be predictors of mortality in HIV-negative 
cryptococcosis patients [69,121] Previous results emphasize that disseminated cryptococcosis 
among HIV-negative patients experienced the worst prognosis secondary to the stage of 
underlying disease and the immunosuppressive medication used [21,56].  It has been clearly 
shown in the HIV-positive population with cryptococcal disease that stage of HIV is strongly 
associated with poor outcome [122].  The underlying disease and its stage are a major factor 
in cryptococcosis outcome. 
Since delay in diagnosis may be a prognostic factor, we investigated whether there 
were additional differences in symptoms and laboratory findings between the three groups.  
There were little differences between HIV-infected patients and transplant recipients who 
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generally had similar symptoms and CSF laboratory parameters.  However, headaches 
(known to be a prognostic factor) [19], were similar between both HIV-negative groups and 
significantly more prevalent in the HIV-positive group.  While all three groups had a high 
prevalence of poor prognostic signs such as altered mental status (~1/3), the presence of 
nausea and vomiting were less common in the HIV-negative/non-transplant group with 
severe disease.  These findings differ from another study that reported significantly more 
mental status changes in non-immunosuppressed patients compared to HIV-positive patients 
[62].  Additionally, our study supports previous evidence that suggests non-
immunosuppressed patients have less fungemia [69].  The HIV-negative/non-transplant 
group also appeared to present with a smaller burden of yeasts by India ink and CRAG test 
results than the other two groups.  Although appreciation for burden organisms and outcome 
could not be precisely understood in this retrospective review, prospective studies of 
cryptococcal meningitis may benefit from quantification of viable yeasts in the CSF (Colony-
forming unit [CFU]/mL measurements) and understanding its rate of change during therapy 
in relationship to treatment strategy and outcome [78,90,123].   
Importantly, compared to HIV-positive and transplant recipients, the attributable 
mortality in the HIV-negative/non-transplant population with severe disease was nearly two-
times higher despite the fact that the majority of patients received induction therapy with a 
polyene and flucytosine.  A recent multi-center study of 86 cryptococcal meningitis patients 
also found the highest mortality in the non-immunosuppressed group (46%) compared to 
immunosuppressed (19%) and HIV-positive (15%) cryptococcal meningitis patients [62], and 
previous studies have reported 30 - 44% overall mortality in the HIV-negative population 
[21,68,69,70].  In one of these studies this rate was compared to a 22% mortality among 
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HIV-positive patients [69].  However, a couple of these studies included some C.gatii cases 
so that species’ factors may have influenced outcome [69,70].  Clearly more studies to 
inform the management of the HIV-negative/non-transplant group and to understand how 
host immunity and yeast strain may play a role in poorer prognosis are needed so as to reduce 
this elevated mortality.   
One of the major complications of cryptococcosis management has been the 
identification and management of IRIS. We identified the occurrence of IRIS in all three 
groups but the prevalence (3%) was relatively low compared to other studies which primarily 
included AIDS patients (range, 8–19%) [92,93,124,125]. This frequency could be influenced 
by our definition of IRIS, the patient mix, and/or clinical management.  In general, our 
HAART management was delayed (>60 days after start of induction therapy) and only 
approximately a quarter of the transplant recipients had their immunosuppressants adjusted.  
This lack of immune manipulation during early induction therapy may influence our lower 
rate of IRIS.  However, it is identified in a measureable amount of all patient groups and 
needs to be appreciated by clinicians. 
Lipid formulations of amphotericin B outside of HIV-infected patients [73,126] have 
limited critical appraisal of proper dosing and efficacy. However, as Figure 2 demonstrated, 
there is a general increase in the use of lipid formulations for induction therapy at our 
institution.  We expect this was in relationship to the approximately third of patients who 
develop nephrotoxicity during management.  Therefore, further investigation into lipid 
products of amphotericin B is still warranted to ensure their optimal use. 
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Limitations 
This review was limited to a single tertiary care center and teaching hospital.  Our 
medical center averaged nearly 15 cases of cryptococcosis per year and this likely reflects 
both an endemic exposure to this yeast in the environment within the Southeastern USA and 
an enriched population of immunosuppressed individuals due to our hospital’s care patterns.  
The actual number of cases seen in a particular medical center certainly varies within the 
U.S.  Furthermore, using hospital records favors cases with severe disease and could result in 
selection bias against asymptomatic disease.  Determining the total population-at-risk was 
not estimable in this study and the underlying source population and referral patterns could 
shift over time.  Retrospective chart review has the potential for incomplete or incorrect 
information capture due to loss of paper documentation or lack of entry in electronic medical 
record.  We used both sources to ensure data was as complete as possible and discrepancies 
were minimized.  Erroneous self-report of symptoms or symptom duration was a possibility, 
but this is a limitation of many observational clinical studies.  Despite our careful abstraction 
process, missing or incomplete data could lead to bias in categorization of symptoms or 
derived outcome definitions, such as IRIS.  Being a rare disease, limited numbers of cases 
prevented robust statistical analyses, although this study is one of the largest to date.  
Importantly, much of the clinical attention over the last two decades has centered around two 
groups (HIV-infected and transplant recipients).  There has been less focus on treatment of 
HIV-negative/non-transplant patients and yet this group suffered the highest mortality.  
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Conclusion 
In summary, dividing patients with cryptococcosis into three risk groups showed both 
differences and similarities within the groups.  In a single medical center the overall 
frequency of cryptococcosis has not changed though the composition of the three groups has 
changed in the last two decades. Despite three major classes of drugs to treat severe disease 
and a relatively uniform and informed treatment strategy framed by the IDSA Guidelines, 
attributable mortality was common.  Prospective multi-center studies and comparison of 
strategies in advanced medical centers are still needed to determine the extent high mortality 
revolved around underlying disease, high burden of organisms and delayed diagnosis.   
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Tables 
Table 4.1.  Patient characteristics at baseline.  Primary diagnosis, disease severity, basic 
patient characteristics and underlying condition of cryptococcosis patients at DUMC 
(N=207). 
    Underlying Condition
a
  
  Total  HIV Transplant HIV-/Trans-
b
  
Category Subcategory N (%)  n (%) n (%) n (%) p-value
c
 
Primary Diagnosis            
 CNS  126 (61)  74 (86) 18 (43) 34 (43) >0.05 
 Pulmonary  71 (34)  9 (10) 24 (57) 38 (48)  
 Other 10 (5)  3 (3) 0 (-) 7 (9)  
Disease severity            
 Severe  131 (63)  74 (86) 18 (43) 39 (49) >0.05 
 Non-severe  76 (37)  12 (14) 24 (57) 40 (51)  
Demographics            
 Male Gender  135 (65)  55 (64) 28 (67) 52 (66) >0.05 
 Black Race 106 (51)  69 (80) 13 (31) 24 (30) >0.05 
 Age (yrs)
d
 47 (15)  40 (9) 50 (14) 54 (18) <0.05 
a 
There were
 
86 patients in the HIV group, 42 in transplant and 79 in HIV-negative, non-transplant.   
b
 HIV-negative and non-transplant  
c
 Cochran Mantel-Haenszel Chi-square test for a general association between the three groups; Kruskal-Wallis 
test for difference between median age was used. 
d
 Instead of n (%), mean (STD) are shown for age.  
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Table 4.2.  Presenting symptoms and risk factors of cryptococcosis disease (N=207) stratified by disease severity at initial presentation 
and underlying condition. 
  Severe  disease (n=131)
a
 Non-severe disease (n=76)
a
 
  HIV Transplant HIV-/Trans-  HIV Transplant HIV-/Trans-  
Presentation Characteristic n (%) n (%) n (%) *p<.05
b
 n (%) n (%) n (%) *p<.05
b
 
Symptoms                 
 No symptoms 1 (1) 0 (-) 0 (-)  1 (8) 10 (42) 9 (23)  
 Altered mental status 22 (30) 7 (39) 17 (44)  0 (-) 1 (4) 0 (-)  
 Headache  54 (73) 9 (50) 17 (44) * 2 (17) 3 (13) 2 (5)  
 Cough  15 (20) 1 (6) 3 (8)  7 (58) 3 (13) 11 (28) * 
 Shortness of breath 10 (14) 1 (6) 5 (13)  6 (50) 5 (21) 14 (35)  
 Night sweats 5 (7) 2 (11) 1 (3)  4 (33) 2 (8) 4 (10)  
 Fever 40 (54) 7 (39) 12 (31)  6 (50) 4 (17) 15 (38)  
 Nausea 33 (45) 11 (61) 6 (15) * 2 (17) 5 (21) 5 (13)  
 Vomiting 28 (38) 8 (44) 5 (13) * 3 (25) 3 (13) 3 (8)  
 Seizures 8 (11) 0 (-) 3 (8)  0 (-) 0 (-) 1 (3)  
Condition/risk factor                
 Renal insufficiency  3 (4) 10 (56) 5 (13) * 3 (25) 6 (25) 6 (15)  
 Liver insufficiency  1 (1) 0 (-) 6 (15) * 1 (8) 0 (-) 2 (5)  
 Hematologic malignancy 0 (-) 1 (6) 7 (18) * 0 (-) 0 (-) 7 (18) * 
 Non-hematologic 
Malignancy  
0 (-) 0 (-) 2 (5)  1 (8) 0 (-) 3 (8)  
Immunosuppressants                
 Corticosteroid 4 (5) 17 (94) 19 (49) * 1 (8) 22 (92) 12 (30) * 
 Calcineurin inhibitor 0 (-) 15 (83) 0 (-) * 0 (-) 21 (88) 2 (5) * 
 Mycophenolate mofetil 0 (-) 13 (72) 2 (5) * 0 (-) 10 (25) 2 (5) * 
 Azathioprine 0 (-) 2 (11) 1 (3) * 0 (-) 8 (33) 1 (3) * 
 Methotrexate 0 (-) 1 (6) 1 (3)  0 (-) 3 (13) 3 (8)  
 Monoclonal antibodies 1 (1) 2 (11) 3 (8)  0 (-) 0 (-) 2 (5)  
 Sirolimus 0 (-) 2 (11) 0 (-) * 0 (-) 2 (8) 0 (-)  
a 
Severe disease: HIV group had 74 patients, transplant group had 18 patients and 39 patients were in the HIV-negative/non-transplant group; Non-severe disease: 
HIV group had 12 patients, transplant group had 24 patients and 40 patients were in the HIV-negative/non-transplant group.  
b
 Cochran Mantel-Haenszel Chi-square test for a general association between the three groups.
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Table 4.3. Differences in mean duration of symptoms (days) reported prior to presentation 
among those reporting any symptom(s) of cryptococcosis (N=156). 
 Severe disease  Non-severe disease 
Underlying condition n Mean  Difference  95% CL
a
  n Mean  Difference 95% CL
a
 
HIV-negative, non-transplant 36 44 0 (ref.)  20, 68  21 66 0 (ref.)  29, 103 
HIV positive 65 19 -25 -50, 1  10 26 -40 -80, 0 
Transplant recipient 14 24 -20 -48, 8  11 20 -46 -84, -8 
Total 114 28   19, 37  42 44   24, 64 
a
 Unadjusted 95% Confidence Limits (CL) of the difference in means.  The 95% CL for the referent group and 
the total are surrounding their corresponding mean (days).  
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Table 4.4.  Diagnostic findings of cryptococcosis disease (N=207) stratified by disease severity at initial presentation and underlying 
condition. 
  Severe disease (n=131)
a
 Non-severe disease (n=76)
a
 
  HIV Transplant HIV-/Trans-  HIV Transplant HIV-/Trans-  
Diagnostic  Result description n (%) n (%) n (%) *p<0.05 n (%) n (%) n (%) *p<0.05 
Positive culture                 
 CNS, first LP
b
 61 (82) 18 (100) 22 (56)  0 - 0 - 0 -  
 Blood
c 
 35 (47) 8 (44) 11 (28)  6 (50) 2 (8) 5 (13) * 
 Pulmonary 6 (8) 2 (11) 3 (8)  2 (17) 13 (54) 21 (53)  
Initial LP
b
                
 CSF CRAG titer ≥1:1024 35 (47) 6 (33)  8 (24)  0 - 0 - 0 -  
 CSF:serum glucose ratio <0.6 66 (89) 16 (89) 28 (85)  7 (64) 7 (39) 6 (27)  
 CSF glucose ≤40mg/dL 43 (58) 11 (61) 20 (61)  1 (0) 1 (6) 0 -  
 CSF protein ≥45mg/dL 66 (89) 16 (89) 32 (97)  6 (55) 14 (78) 9 (41) * 
 Nucleated cells >20cells/mm
3, d
 30 (48) 14 (78) 20 (71) * 0 - 0 - 0 -  
 OP ≥20cm H2O 47 (64) 11 (61) 17 (52)  6 (55) 3 (17) 4 (18)  
 Positive India Ink  41 (55) 9 (50) 11 (33)  0 - 0 - 0 -  
Other                 
 Serum CRAG titer ≥1:1024 47 (64) 11 (61) 17 (44)  5 (42) 3 (13) 4 (10) * 
 Other histological evidence  9 (12) 3 (17) 6 (15)  0 - 15 (63) 27 (68) * 
a 
Severe disease: HIV group had 74 patients, transplant group had 18 patients and 39 patients were in the HIV-negative/non-transplant group; Non-severe disease: 
HIV group had 12 patients, transplant group had 24 patients and 40 patients were in the HIV-negative/non-transplant group.  
b
 Lumbar puncture; 176 total patients had an LP; percentages relevant to the LP procedure reflect missing observations.  Six HIV-negative, non-transplant 
patients with severe disease did not receive an LP (n=33). 25 patients without an LP (to rule out CNS disease) were non-severe cases: one HIV-positive, six 
transplant recipients, and 18 HIV-negative/non-transplant patients.   
c
 OP = Opening pressure 
d
 Eleven (15%) HIV-infected patients had missing documentation of CSF host (nucleated) cells (overall N=63); excluding the six with no initial LP, five HIV-
negative, non-transplant were missing host cell counts (overall N=28). 
e 
Opening pressure; maximum LP OP was used for this variable, as initial LP OP was infrequently captured.  Denominators for each group with severe disease 
were 74, 8, and 33, respectively. 
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Table 4.5.  Patient treatment and outcomes.  Initial antifungal regimen used for induction therapy, patient mortality through one 
year, and immune reconstitution inflammatory syndrome (IRIS) by primary disease diagnosis (severe or non-severe) and major 
underlying condition (HIV, transplant, or HIV-negative and non-transplant).   
    Severe disease (n=131)
a
  Non-severe disease (n=76)
a
 
  Total  HIV Transplant HIV-/Trans-
b
  HIV Transplant HIV-/Trans-
b
 
Outcomes Description N (%)  n (%) n (%) n (%)  n (%) n (%) n (%) 
Initial therapy                  
 AmpBd alone 18 (9)  7 (9) 1 (6) 5 (13)  1 (8) 2 (8) 2 (5) 
 AmpBd+5FC 88 (43)  55 (74) 5 (28) 22 (56)  1 (8) 0 (-) 5 (13) 
 LFAmpB alone 7 (3)  1 (1) 2 (11) 1 (3)  0 (-) 1 (4) 2 (5) 
 LFAmpB+5FC 19 (9)  3 (4) 10 (56) 6 (15)  0 (-) 0 (-) 0 (-) 
 Fluconazole 71 (34)  8 (11) 0 (-) 2 (5)  10 (83) 21 (88) 30 (75) 
 Voriconazole 1 (<1)  0 (-) 0 (-) 1 (3)  0 (-) 0 (-) 0 (-) 
 None 3 (1)  0 (-) 0 (-) 2 (5)  0 (-) 0 (-) 1 (3) 
Result
c
                  
 Attributable death 31 (15)  12 (16) 3 (17) 12 (31)  1 (8) 0 (-) 3 (8) 
 Overall mortality 52 (25)  15 (20) 5 (28) 16 (41)  2 (17) 1 (4) 13 (33) 
 IRIS 7 (3)  3 (4) 2 (11) 1 (3)  1 (8) 0 (-) 0 (-) 
a 
Severe disease: HIV group had 74 patients, transplant group had 18 patients and 39 patients were in the HIV-negative/non-transplant group; Non-severe disease: 
HIV group had 12 patients, transplant group had 24 patients and 40 patients were in the HIV-negative/non-transplant group.  
b 
HIV-negative, non-transplant  
c
 Cochran Mantel-Haenszel Chi-square test for a general association between the three groups was significant for overall mortality among non-severe disease 
only. 
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Figures 
 
 
Figure 4.1. Annual cases.  Annual frequency of severe and non-severe cryptococcosis cases 
according to underlying condition (N=207).   
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Figure 4.2. Use of amphotericin B.  Amphotericin B formulation trends over time. Annual 
percentage of patients receiving lipid formulation amphotericin B (LF AmpB) or 
deoxycholate amphotericin B (AmpBd) for initial therapy (N=132).   
  
  
CHAPTER V.  APPROACHES TO ANTIFUNGAL THERAPY AND THEIR 
EFFECTIVENESS AMONG PATIENTS WITH CRYPTOCOCCOSIS  
 
Overview 
 
The goal of this study was to determine the degree to which the persistence of 
cryptococcosis, overall 1-year mortality, and 1-year mortality due to cryptococcosis were 
influenced by initial antifungal treatment regimen in a cohort of adults with cryptococcosis 
treated at a tertiary care medical center.  Risk factors, underlying conditions, treatment and 
mortality information were obtained for 204 adults with cryptococcosis from Duke 
University Medical Center (DUMC) from 1996-2009.  Adjusted risk ratios (RR) for 
persistence and hazard ratios (HR) for mortality were estimated for each exposure. 
All-cause mortality among patients with non-severe disease (20%) was similar to the 
group with disease (26%). However, cryptococcosis-attributable mortality with non-severe 
disease (5%) was much lower than with severe disease (20%).  Flucytosine exposure was 
associated with a lower overall mortality rate (HR 0.4, 95%CI 0.2 – 0.9) and attributable 
mortality (HR 0.5, 95%CI 0.2 – 1.2).  Receiving a non-recommended antifungal regimen was 
associated with a higher relative risk of persistent infection at four weeks (RR1.9, 95%CI 0.9 
– 4.3) and the rate of attributable mortality among those not receiving the recommended dose 
of initial therapy was higher relative to those receiving recommended dosing (HR 2.3, 
95%CI 1.0 – 5.0).  
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Thus, the 2010 IDSA Guidelines are supported by this retrospective review as a best-
practice protocol for cryptococcal management.  Future investigations should consider 
highlighting the distinction between all-cause and attributable mortality as not to 
overestimate the true effect of cryptococcosis on patient death.  
 
Introduction  
 
The optimal antifungal treatment strategy for patients with cryptococcosis remains in 
question despite the 2010 Infectious Disease Society of America Guidelines [1].  Treatment 
of cryptococcal meningoencephalitis is based on a small number of clinical trials, but most of 
the recent studies have been in resource-limited areas and may not reflect the situation with 
newer antifungals in advanced medical settings [106,127,128,129].  Previous studies have 
suggested that treatment is generally 50-80% effective [3,4,18,22], that antifungal drugs 
cause toxicities in roughly one-third of cases, that mortality while on antifungal therapy 
remains high (approximately 20%)  and that mortality varies considerably by the host 
underlying immune status [13,21,44,48,62].  
There have been few comprehensive, comparative studies of cryptococcosis that 
encompass all three risk groups (HIV positive, solid organ transplantation and HIV-
negative/non-transplant) with and without meningeal involvement, identified by the 2010 
IDSA Guidelines in the era of lipid products of amphotericin B.  Therefore, we examined the 
effectiveness of initial antifungal treatment among these three clinical groups within a single 
study-center.  The primary aim of this study was to determine the degree to which the risk for 
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persistence of cryptococcosis, rates of 1-year mortality and mortality due to cryptococcosis 
were influenced by initial antifungal treatment regimen in a cohort of patients with 
cryptococcosis treated at a tertiary care medical center.  The advantage of this approach was 
to observe real world treatment strategies and compare risk groups where anti-cryptococcal 
drugs are available and the general care and management of this infection has been relatively 
consistent over the 14-year study period.  Other treatment-related outcomes examined were: 
(1) changes from initial therapy to definitive therapy (2) development of renal toxicity, (3) 
development of Immune Reconstitution Inflammatory Syndrome (IRIS), (4) and number of 
cases requiring multiple courses of induction therapy using amphotericin B. 
 
Methods  
 
Study population 
 All consecutive 204 adults hospitalized with cryptococcosis and who were treated at 
DUMC were enrolled in the cohort using ICD-9 discharge codes of cryptococcosis (117.5), 
and cryptococcal meningitis (321.0) from 1996-2009.  Three identified patients were 
excluded from this cohort because they had died prior to receiving any anti-cryptococcal 
therapy or refused treatment at DUMC.  Risk factors, underlying conditions, treatment and 
mortality information were obtained by chart review.  Patients presented to DUMC, were 
diagnosed with cryptococcosis and were assessed for severity of disease prior to starting 
treatment.  “Severe” and “non-severe” cryptococcosis disease categories divided patients 
who required induction therapy with amphotericin B (severe disease) and those where 
fluconazole was indicated as primary therapy (non-severe disease) based on the IDSA 
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Guidelines [1], whether or not the patients actually received the indicated treatment.  Follow-
up started when initial treatment was given, preceded by the occurrence of disease, patient 
admission, followed by the assessment of cryptococcosis severity. 
 
Exposures 
 There were three main treatment exposures of interest: (1) appropriate initial 
treatment, (2) appropriate initial treatment dose, (3) and appropriate flucytosine (5FC) use 
based on IDSA recommendations.  Secondary treatment-related exposures of interest 
included the completion of at least 7 days of flucytosine combination antifungal therapy 
versus not receiving it or completing <7 days, confined to patients with severe disease, 
completion of at least 30 days of fluconazole therapy among surviving patients (non-severe 
disease), and completion of at least 90 days of fluconazole therapy among surviving patients 
(non-severe disease).    
Patients were categorized by whether or not their initial antifungal drug and dosing 
were ‘appropriate’ using the 2010 IDSA Guidelines.  Flucytosine exposure at the start of 
induction therapy was assessed among patients with severe disease.  “Initial therapy” refers 
to the first antifungal drug administered at the start of induction treatment.  This excludes 
subsequent switching from this initial drug to another formulation during the same induction 
period (e.g. deoxycholate to lipid amphotericin B).  An exception to this definition was the 
use of fluconazole prior to confirmation of disease, where a patient was then placed on an 
amphotericin B regimen.  Furthermore, fluconazole exposure was not considered as initial 
therapy if it was administered for ≤5 days after the first positive culture result before 
amphotericin B began, else fluconazole would be considered as initial therapy.   
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In order to account for initial dosing adjustments that can occur in the first few days 
of induction, the averaged dose of continuous antifungal therapy (no change of drug or 
interruption of treatment ≥3 days) was used to define acceptable dosing of initial therapy.  If 
there was a change from initial therapy (excluding flucytosine), then only the first drug and 
its corresponding average dosing was used to examine appropriate initial therapy dose.  
Acceptable dosing was defined as follows:  0.7-1.0mg/kg/day amphotericin B deoxycholate 
(AmpBd), 3-6mg/kg/day liposomal AmpB (L-AmpB), 4-6mg/kg/day AmpB lipid complex 
(ABLC), and ≥400mg/day fluconazole.  Rounding to the nearest tenth for AmpBd and the 
nearest integer for AmpB lipid products were used to categorize appropriate dosing.  Dosing 
of flucytosine was not examined in this study.  Cumulative doses among patients who 
survived long enough to complete the recommended length of treatment (14 days for severe, 
90 days used for non-severe) were summarized (Appendix B). 
 
Outcomes 
 Follow-up time started when anti-cryptococcal therapy was initiated after patient 
admission, diagnosis and severity evaluation were complete.  We assessed persistent 
infection at two (severe disease only) and four weeks, cryptococcal-attributable mortality and 
all-cause mortality through one year of follow-up.  Two and four weeks were chosen because 
severe disease patients are recommended to receive at least two weeks of induction therapy 
and reliable follow-up and mortality information was available for the majority of surviving 
cases.  Figure 5.1 illustrates overall patient flow.  Follow-up for this study began at the start 
of anti-cryptococcal therapy up to four weeks to evaluate persistence and up to one year for 
mortality outcomes.   
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Persistent cryptococcosis was defined as having a positive culture(s) two weeks after 
starting therapy (among severe disease group only) and persistent cryptococcosis at four 
weeks was having a positive culture(s) and/or positive indication of the presence of 
cryptococcal-related symptoms four weeks after starting therapy.  Patients had to have 
survived until the time of measurement to be included in the analysis.  Data were 
observational; measures for indicating persistent infection were not taken at exactly two 
weeks and four weeks to test for positive culture, cryptococcal antigen (CRAG), and/or 
infection-related symptoms.  Acceptable values were used if they did not overlap with the 
preceding measurement (e.g. a baseline culture could not be used for a two week test result), 
and did not extend beyond the designated time point (e.g. a three-week measure would not be 
counted as a two-week measure, but instead a four-week measure if there was not an 
observation at four weeks).  Persistence measures for two weeks had to have occurred ≥1 
week of therapy. Measures beyond the final time point (4 weeks) were accepted for that final 
time point if it was within 90 days since starting therapy. 
 In order to assess one-year mortality, we obtained data on survival and mortality up to 
one year after their date of cryptococcosis diagnosis from the Duke Data Support Repository 
(DSR), which uses the Social Security Administration death index, the Tumor Registry and 
The Duke Information System for Cardiovascular Care death data to report mortality status.  
If the patient died beyond one year of follow-up or was alive or lost to follow-up at the end 
of the study period, they were censored subjects.  Attributable mortality within one year from 
the start of anti-cryptococcal therapy was determined by a panel of experts that death was 
due to conditions related with at least one of the following:  increased CNS pressure, 
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persistent infection, relapse of infection, while on treatment for cryptococcosis and an 
underlying disease, or organ failure while on antifungal treatment.   
 Additional outcomes for both severe and non-severe cryptococcosis patients included 
frequency of re-induction(s) with amphotericin B, IRIS and renal toxicity during initial 
therapy.  Renal toxicity was defined as a >50% decrease in Glomerular Filtration Rate 
(GFR), also known as estimated creatinine clearance, during initial induction treatment.  
GFR was calculated using the CKD-EPI (Chronic Kidney Disease Epidemiology 
Collaboration) formula [99].  For patients with severe disease who received induction 
therapy with amphotericin B, creatinine values closest to day 0 and day 14 of treatment were 
used to determine renal toxicity.  The definition for IRIS (adapted from Perfect and Singh, 
2007) has been previously described (Bratton et al, 2012, in production; see Chapter Four). 
  For severe and non-severe disease groups, the dynamics of changing from one 
treatment regimen to another was compared to patients who received uninterrupted 
antifungal therapy.  Lastly, we estimated the association between patients who received 0 – 7 
days of flucytosine compared to those who received more than 7 days of flucytosine on the 
risks of persistence and mortality among two-week survivors with severe disease. 
 
Data analysis 
To evaluate issues of confounding, we assessed the bivariate associations between all 
covariates and main exposures and outcomes.  Minimum adjustment sets were determined 
using Directed Acyclic Graph (DAG) program (v0.21) [100].  However, the program resulted 
in 14 confounders in the minimum adjustment sets for each of our three chosen exposures 
(with slight variation; Figures 3.2 and 3.3), of which our limited study size could not 
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operably model.  Based on previous studies that predicted poor outcomes 
[13,15,16,17,18,19,20,21], we prioritized variables associated with severe underlying 
condition and high fungal burden from our minimal adjustment sets and proceeded with  
multivariate adjustment using a change-in-estimate approach with a 10% cut-off criterion 
[101]; eliminating variables chosen by the DAG program that did not confound the 
association of effect estimates between the main exposures and outcomes.  Changes in the 
precision of estimates were examined with the confidence limit interval (CLR); covariates 
that improved precision were maintained in the final model.  Effect measure modification by 
confounding variables was examined through the inclusion of interaction terms in the models 
and using the spreadsheet by Andersson et al. (2005) to determine the relative excess risk due 
to interaction (RERI)[102].   
Binomial regression was used to estimate the risk ratio (RR) of the association 
between treatment exposures and these outcomes.  If the binomial model failed to converge, 
a scaled Poisson distribution was used for robust estimation.  Cox proportional hazards 
models were used to estimate hazard ratios (HR) for the association between treatment 
exposures and mortality outcomes.  Assessment of the proportional hazards assumption 
(PHA) was performed using graphical methods (ln – ln survival plot) and by adding an 
interaction between each of the model predictors and (log) time. Corresponding 95% CIs 
were estimated to measure the precision for each estimate of exposure and outcome 
association.   
Abstraction forms were entered into Microsoft Office Access (2007) and data 
analyses were performed using SAS v9.2 (SAS Institute, Cary, North Carolina). Investigators 
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recorded all information on a standardized abstraction form developed in collaboration with 
epidemiologists and clinicians.   
Research Ethics 
This study was approved by both the Duke University Medical Institutional Review 
Board (IRB) and the University of Chapel Hill Biomedical IRB.  Both named IRBs waived 
the need for informed consent for this study. This research met criteria for a waiver of 
informed consent according to 45 Code of Federal Regulations (CFR) 46.116(d).  
 
Results  
 
Baseline Characteristics 
There were 204 patients with records describing their antifungal treatment; 129 (63%) 
patients had severe disease defined as requiring amphotericin B induction treatment and there 
were 75 (37%) patients treated with fluconazole as recommended for non-severe disease.   
Transplant recipients were the smallest group (n=42, 21%) and HIV-positive (n=85, 42%) 
and HIV-negative, non-transplant patients (n=77, 38%) composed the remainder of the 
cohort.  The majority of patients presenting at DUMC had CNS disease (n=126, 62%) and 
pulmonary disease was seen in about a third of all cases (n=69, 34%).  In addition to CNS 
disease patients, three patients from the ‘other’ disease category (n=9, 4%) also fit the 
definition for severe disease requiring amphotericin B induction treatment.  There were 
32,801 total days of follow-up accrued among patients with severe cryptococcosis and 
20,439 days of follow-up among patients with non-severe cryptococcosis.  Average length of 
follow up did not differ substantially between groups (mean: 254 days for severe disease and 
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273 days for non-severe disease) and averages were also similar across treatment exposure 
strata.   
Patients differed considerably with regard to presenting symptoms and conditions 
based on severity of cryptococcosis, although the duration of symptoms prior to presentation 
was similar in range.  As expected, patients with non-severe cryptococcosis (n=75) had fewer 
neurological symptoms than CNS cases.  Diagnostically, the proportion of patients with a 
maximum opening pressure of 20cm H2O was high for both severe (42%) and non-severe 
(65%) cryptococcosis patients, although one-third of non-severe patients did not undergo a 
Lumbar puncture (LP).  If we assumed that all non-severe patients without a LP were 
negative for elevated opening pressure, the proportion of patients with an elevated opening 
pressure was 44%. 
Baseline covariate measures prior to starting therapy according to patient status 
regarding our four main treatment exposures are shown in Tables 5.1 and 5.2.  Patients who 
received their recommended therapy and severe disease patients who received flucytosine 
combination therapy had higher frequencies of symptoms and diagnostics indicating CNS 
disease (headache, vomiting and nausea, altered mental status, high CRAG titers), compared 
to patients who did not receive the recommended initial therapy.  This trend was not seen 
when looking at initial treatment dose, which showed very few variations in covariate 
frequencies between exposure groups, except for altered mental status and high serum CRAG 
titer (Table 5.1, Table 5.2).   
Severe disease patients who received flucytosine combination initial therapy had 
lower frequencies of pulmonary symptoms (shortness of breath and cough), but a higher 
proportion of patients had a longer duration of symptoms (≥14 days) and diagnostic evidence 
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of CNS disease (India ink, high CSF CRAG titer), compared to those who did not receive 
flucytosine (Table 5.1).  Patients given a shorter length of flucytosine exposure (0 – 7 days) 
had a higher proportion of cases taking corticosteroids at the time of diagnosis, reported 
weight loss, and HAART exposure (among HIV-positive patients) compared to patients 
given ≥ 7 days of flucytosine, who had a higher proportion of patients with positive blood 
and CNS cultures, India ink and organ transplant recipients (Table 5.1, Table 5.2).  
 
Antifungal Treatment  
Initial antifungal therapy type was considered “appropriate” given disease severity for 
the majority of patients (88%; Table 5.3).  Only 11 patients (9%) with severe disease (n=129) 
were not given amphotericin B therapy within 5 days of starting therapy—seven of these 
patients were eventually given polyene treatment (Table 5.3).  Fourteen patients (19%) that 
fulfilled the definition of non-severe cryptococcosis did not receive fluconazole for initial 
antifungal therapy.  Rather, amphotericin B was used.  Given the severity of disease, 
appropriate therapy was similar in prevalence between underlying risk groups:  88% (n=75) 
of HIV-positive patients received appropriate therapy, 84% (n=39) of transplant recipients 
and 93% (n=65) of HIV-negative/non-transplant patients received appropriate antifungal 
therapy. 
 There were 192 patients (94%) with available initial treatment dose information 
(Table 5.4).  The mean dose of AmpBd was 0.66 mg/kg/day (interquartile range [IQR]: 0.56 
– 0.73 mg/kg/day). Mean doses for lipid products of amphotericin B were similar and 
generally in the recommended range, but ABLC was used more often and slightly higher in 
doses than L-AmpB (Table 5.4).  The fluconazole dose averaged 350mg/day (IQR:  208-400 
 85 
mg/day; Table 5.4), which was close to the recommended ≥400mg/day for primary therapy 
and was lowest for HIV-positive patients (data not shown).   
Overall, 66% of patients received appropriate dosing of their initial therapy (Table 
5.4). Dosing for severe patients was outside the recommended range for 42 (36%) patients 
and this was similar for non-severe patients (n=24, 32%).  Furthermore, 43% of patients who 
received AmpBd and 27% of patients who received fluconazole did not receive appropriate 
dosing of therapy, while approximately 13% of patients who received LFAmpB did not 
receiving appropriate dosing. Among patients with severe disease, AmpBd formulation was 
within the recommended range of 0.7 – 1.0 mg/kg/day for 50 patients (57%; Table 5.4), and 
tended to be outside the recommended range for HIV-negative patients in particular (data not 
shown).  Median cumulative dose of initial therapy for patients who did not switch therapy is 
shown in supplemental information (Appendix B).   
 
Treatment for Severe Disease 
 Flucytosine (5FC) was incorporated into initial therapy in 77% of patients with severe 
cryptococcosis (Figure 5.2).  In this group, 79% of HIV-positive patients received flucytosine 
with initial therapy; 83% of transplant patients and 70% of HIV-negative/non-transplant also 
received flucytosine in combination with amphotericin B.  The mean number of days of 
initial flucytosine was 11.8 days (standard deviation [SD] ± 6.3 days).  Only 37% of patients 
who received flucytosine continued the drug for at least 14 days as recommended (Figure 
5.2).   
 Among patients who received any formulation of amphotericin B as initial therapy 
(n=118) and survived at least 14 days since the start of therapy (n=106), 56 patients (53%) 
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completed ≥14 days of amphotericin B treatment.  Seventy-five patients (58%) did not switch 
from their initial amphotericin B formulation (Table 5.3).  Among the 14-day survivors 
(n=106), patients who switched from their initial amphotericin B treatment experienced 
significantly longer treatment exposure than those who did not (difference in means=6 days, 
95% CI 3 – 9 days).    
  
Treatment for Non-severe Disease 
Most non-severe disease patients (81%) received fluconazole as initial antifungal 
therapy (Table 5.3).  There were 10 (13%) patients with non-severe disease who later 
changed initial treatment compared to 50 (39%) severe disease patients (Table 5.3).  This 
continuity of initial therapy was significantly higher than that among patients with severe 
disease (RRcrude 1.4, 95% CI: 1.2 – 1.7).  Of the patients given fluconazole as initial therapy, 
33 patients (54%) completed 90 days of treatment, while prior to 90 days two patients were 
lost to follow-up and six died (one attributable to cryptococcosis).  Fifty-two patients (72%) 
completed 30 days of fluconazole treatment among those surviving at least that long (N=72).   
 
Persistence of Cryptococcosis  
Persistence of infection was common two weeks after starting therapy (47%, Table 
5.5) among patients with severe disease.  Overall persistence at four weeks after starting 
therapy was 25%; 33% among severe and 11% among non-severe patients.  
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Patient Mortality 
Mortality in the first year after starting cryptococcosis treatment was high (Table 5.5) 
with attributable mortality through one year of 15% (n=30).  All-cause mortality through one 
year of follow-up was 25% (n=52).  Notably, half of these deaths (n=15) were among HIV-
negative/non-transplant cases.  Acute mortality was high among patients with severe disease.  
Twenty-six (20%) patients died due to cryptococcosis and half of these were during the first 
two weeks while receiving induction treatment; three additional patients died through four 
weeks of follow-up.  Among patients with severe disease, 10 (10%) who did not complete 
full induction therapy died.  Of those who did not switch from their initial amphotericin B 
therapy (n=75), there were 12 deaths attributable to cryptococcosis (16%), which was similar 
to the 9 deaths among the 43 patients (21%) who changed their amphotericin B induction 
regimen.  Non-severe disease patients had lower mortality; three deaths (5%) occurred within 
the first month of follow-up from the start of initial therapy.   
 
Appropriate Initial Treatment 
The risk of persistence two weeks from starting therapy among surviving severe 
disease patients who did not receive recommended treatment was 1.4 (95% CI 0.6 – 3.0) 
relative to those who received appropriate initial therapy (Table 5.6).  The risk of persistence 
at four weeks out from treatment among all surviving patients who did not initially receive 
the recommended antifungal treatment was higher (RR 1.9, 95% CI 0.9 – 4.3; Table 5.6).  If 
patient deaths during two and four weeks were considered persistent infection, the 
corresponding RRs were 1.2 (95% CI 0.6 – 2.7) and 1.6 (95% CI 0.7 – 3.3). 
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The association between appropriate initial treatment and patient mortality was weak 
(Table 5.6).  The adjusted HR cryptococcosis-attributable mortality through one year of 
follow-up for initial treatment was 0.8 (95% CI 0.3 – 1.8).   The hazard of overall mortality 
through one year of follow-up among patients who did not receive the recommended 
antifungal treatment was 1.1 times the hazard of those who received the recommended initial 
treatment (95% CI 0.4 – 3.2), adjusted for underlying hematologic malignancy and severe 
disease. 
 
Appropriate Initial Treatment Dose 
Treatment dose had no discernible association with the outcome of persistence (Table 
5.6).  There was no significant association between the relative risk of persistence at four 
weeks out from treatment among surviving patients who did not receive recommended 
antifungal treatment dosing compared to those who initially received the recommended 
dosing (RR 1.1, 95% CI 0.6 – 1.8).  Among patients with severe disease, the adjusted RR of 
treatment doses outside that of the recommended range and two-week persistence was also 
close to null (Table 5.6).  If patient deaths during two and four weeks were considered 
persistent infection, the corresponding RRs were similar: 1.1 (95% CI 0.9 – 1.4) and 1.2 
(95% CI 0.8 – 1.8). 
The hazard rate of cryptococcosis-attributable mortality among patients who received 
treatment dosing outside what was recommended was 2.3 times the rate compared to patients 
who received the recommended dosing (95% CI 1.0 – 5.0) after adjusting for underlying 
hematologic malignancy, severe disease, and positive blood culture (Table 5.6).The adjusted 
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HR was 1.3 (95% CI 0.7 – 2.4), adjusting for underlying hematologic malignancy and 
positive blood culture.   
 
Flucytosine Use among Severe Cases 
The RR of two-week persistence and receiving flucytosine was similar to four weeks 
(Table 5.6).  Among patients with severe disease (n=129) where flucytosine in combination 
with amphotericin B treatment is recommended, the adjusted risk of persistence at four 
weeks from initiation of treatment among surviving patients who received flucytosine as part 
of initial therapy was 0.6 times the risk of those who did not receive any flucytosine (Table 
5.6; 95% CI 0.3 – 1.3).  If patient deaths during two and four weeks were considered 
persistent infection, the corresponding estimates were: RR 0.8 (95% CI 0.5 – 1.4) and RR 0.8 
(95% CI 0.4 – 1.4). 
The adjusted hazard of overall mortality through one year of follow-up among 
patients who received flucytosine with their initial antifungal therapy was 0.4 times the 
hazard of those who did not receive flucytosine (95% CI 0.2 – 0.9) (Table 5.6).  The HR of 
attributable mortality through one year of follow-up for flucytosine exposure was similar, 
though less precise (HR 0.5, 95% CI 0.2 – 1.2).   
There was no clear association with risk of persistence (two or four weeks) between 
patients who received >7 days of flucytosine in combination with their primary antifungal 
therapy and those who received ≤7 days (Table 5.6).  Receiving >7 days of flucytosine was 
protective of cryptococcosis-attributable mortality hazard compared to those who received ≤7 
days of flucytosine, though the association was not significant (Table 5.6).   Notably, full 
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flucytosine exposure was not possible for those that succumbed to acute mortality within 14 
days of starting treatment (n=13, 50% of all attributable deaths).   
 
Additional Outcomes 
Re-induction with amphotericin B treatment was performed in 25% (n=29) of severe 
disease patients and 7% (n=5) of non-severe disease patients (Table 5.6).  IRIS was 
diagnosed rarely (n=7; 3%) among all patients surviving through the end of initial therapy, 
and most of these were among patients with severe disease (n=6).   
Pertaining to severe disease patients, renal toxicity during initial treatment occurred in 
approximately one-third of cases (n=33) and 26 of these patients did not complete 14 days of 
induction treatment.  Out of the 33 cases with renal toxicity, 19 (58%) patients switched from 
their initial therapy.  Fifteen of these 19 patients who experienced renal toxicity and switched 
initial therapy did not complete 14 days of induction treatment.  Of the remaining 14 patients 
who experienced renal toxicity but did not switch from their initial therapy, 11 did not 
complete 14 days of induction treatment.   Among the patients surviving at least 14 days 
(eligible to switch therapy within recommended treatment length), evidence of renal toxicity 
was associated with a higher relative risk of switching initial treatment (RRcrude 1.9, 95% CI:  
1.0 – 3.3).     
 
Discussion 
 
This study of cryptococcal management provides important insights into the disease 
in an advanced treatment center and presents additional data and support for the current 
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IDSA Guidelines.  Retrospective reviews have limitations.  However, they can provide 
crucial knowledge into “real world” effectiveness of therapy that is not captured in 
randomized controlled studies.  The outcomes of individual cases are subject to their 
underlying disease, toxicity of medications and difficulties in understanding complications, 
such as IRIS and increased intracranial pressure.  By studying the effectiveness of therapy we 
can evaluate the current standards of care, their real world outcomes, and identify obstacles 
for improving that care.     
There were important differences in symptoms, underlying conditions and diagnostics 
based on cryptococcosis disease severity.  Of note, cerebrospinal fluid opening pressure was 
similar between two divergent groups (one with and one without indicators of central 
nervous system disease) — even when the absence of a lumbar puncture for non-severe 
disease patients was considered negative results.  This result was interesting knowing that the 
non-severe group was negative for central nervous system cryptococcosis.  It demonstrates 
that an elevated cerebrospinal fluid opening pressure in patients with neurological symptoms 
can be an indicator for intracranial management [130], but the potentially low specificity 
observed in our study suggests that it may not serve as a precise diagnostic tool as it is 
presently measured at the bedside with a manometer.  However, in clinical practice 
intracranial pressure measurements are importantly linked to other neurologic symptoms of 
disease such as headache or altered mental status.  All of these factors remain essential for 
treatment and resolution of cryptococcal meningitis [34], but better and more precise 
measurement technology may be warranted.   
 Overall, appropriate initial treatment of cryptococcosis was high over the 14-year 
study period, with a recommended therapeutic regimen being used for 88% of patients and 
 92 
the recommended dosing being followed in 66% of patients.  Despite small numbers and 
retrospective nature of this study, there was favorable evidence for compliance and clinical 
results supporting the IDSA Guidelines.   For instance, patients not receiving initial 
recommended treatment regimens had a higher risk of persistent infection at four weeks (RR 
1.9) and a higher attributable mortality (RR 2.3) in those not receiving the recommended 
dose.  However, over one-third of patients did change from their initial therapy; 28% of these 
patients were switched from a non-recommended to a recommended therapy given their 
disease severity.  The consequences of this change in therapy resulted in patients who 
experienced an overall longer duration of induction compared to those who did not.   
Flucytosine was used in 78% of severe disease patients for initial therapy, but only 
37% of these recipients continued combination treatment for at least 14 days.  High acute 
mortality (prior to completion of induction) and renal toxicity among severe disease patients 
likely contributed to this high incompletion rate.  Nonetheless, patients receiving flucytosine 
combination therapy experienced lower rates of overall and attributable mortality than those 
patients who did not receive any flucytosine.  However, receiving more than seven days of 
flucytosine was not significantly associated with lower mortality rates compared to those 
who received at most seven days, suggesting that early acute mortality may not be 
preventable with flucytosine use, but is a consequence of other underlying factors, such as 
malignancy or AIDS, contributing to poor patient outcome.  On the other hand, the observed 
protective effects of flucytosine supports a growing body of evidence that combination 
therapy is important to a positive outcome [4,13,78].  The polyene and flucytosine 
combination has consistently demonstrated its superior success with retrospective data 
identifying better outcomes at two weeks[4], prospective randomized trial data on fungicidal 
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activity in the CSF [78], and correlation with this fungicidal activity and outcome [87,131].  
Thus, our study highlights the importance for increased use of flucytosine. This may be 
improved with rapid access flucytosine levels and/or close follow-up of complete blood 
counts— elements needed to increase the likelihood patients will receive at least two weeks 
of flucytosine.   
 By our definition persistence at two weeks was a common outcome, but 75% of 
patients through four weeks did have documented resolution of symptoms and 
microbiological signs of disease.   The percent of patients with disease resolution through 
four weeks falls into the same range of outcomes as previously published cohorts [2-5].  This 
persistence of infection rate likely reflects the high burden of Cryptococcus in the CSF of 
these patients and challenges us to be more aggressive about measuring how our treatment 
regimens are impacting the killing of yeasts during induction therapy.  
All-cause mortality of non-severe disease patients (20%) was similar to the severe 
disease group (26%).When comparing cryptococcosis-attributable mortality, non-severe 
disease patient mortality was much lower than severe disease patient mortality (5% and 20%, 
respectively).  Future investigation should consider highlighting the distinction of these two 
mortality outcomes as to not overestimate the true effect of cryptococcosis on patient death. 
This also serves to identify that non-severe disease also does identify a patient with a serious 
underlying disease in many cases.   
This difference between attributable and overall mortality emphasizes how the 
specific underlying disease was a risk factor for poor outcomes.  For example, a hematologic 
malignancy was a strong independent predictor of patient mortality in our cohort and likely 
reflects the end-stage of the underlying disease when cryptococcosis appears [111,115].  
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Fourteen out of 15 patients with hematologic malignancy were HIV-negative and had not 
received a solid organ transplant.  In fact, 50% of cryptococcosis-attributable deaths were in 
HIV-negative, non-transplant patients with a variety of underlying diseases.   Thus, 
identifying background rates of cryptococcosis and baseline risk factors for earlier diagnosis 
and assessing present treatment strategies in relationship to how they are efficiently handling 
the fungal burden could be very useful in reducing morbidity and mortality for this group.  
Four major randomized treatment trials served as important comparators to this study 
and informed the treatment recommendations in the current IDSA Guidelines [13,18,19,22].  
The key differences between these studies and this cohort was that this study was 
observational (non-randomized) and used a single-center instead of multiple sites for patient 
recruitment.  Only one study [13] used a larger patient group for analysis and all but one 
study [19] recruited only cryptococcal meningitis cases.  Our study spanned a much longer 
period of time (14 years compared to ≤5 years for the randomized trials).  The continuity of 
care at a single-center allowed for such an extended period of in-depth retrospective 
observation.  However, there were striking similarities between results in our study to these 
randomized trials.  First, we observed a prevalence of cure or improvement through four 
weeks of 75% and Dismukes et al (1987) observed 80% cure through four weeks [19].  
Second, through two weeks of combination induction therapy van der Horst et al (1997) 
reported 60% patients were culture negative [13].  In our study, 42% patients with severe 
disease had signs of persistent infection through two weeks.  Third, attributable mortality and 
overall mortality were consistent with those found by three other randomized trials 
[18,22,108].  Among patients with severe disease in our study, 10% died in the first two 
weeks.  This sobering figure demonstrates that acute mortality continues to be a serious 
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problem despite over three decades of clinical study and experience.  Fourth, since timing of 
relapse was difficult to categorize in this observational study, re-induction might be 
considered a proxy for relapse—19% of our patients were re-induced.  This finding was 
similar to the prevalence of relapse (16% in six week arm and 27% in four week arm) 
reported by Dismukes et al [19].  This relapse rate may be artificially high secondary to lack 
of IRIS appreciation, although in retrospective in our review, we found a relatively low 
incidence of this condition in our cohort.   
Although an observational study design was used, we observed similar results as 
previous randomized trials.  Taking into consideration our single-center attribute, the 
observed consistency in treatment may have had the unintended consequence of revealing 
underlying factors contributing to patient failure rather than determining whether variations 
in initial treatment were contributing to persistence of cryptococcosis or its attributable-
mortality.  In fact, positive CSF cultures, high CSF antigenemia, absence of headache and 
long duration of symptoms prior to admission continue to emerge in our analyses as strong 
predictors of patient failure rather than treatment regimens.  Within these risk factors are 
likely buried important features of outcome regarding high burden of yeasts and poor host 
inflammatory responses within the CNS which must be carefully defined and monitored in 
relationship to therapy [132]. 
 
Strengths and Limitations 
Our results may not be applicable to all centers in the USA as approaches for 
ancillary care may differ.  Furthermore, using hospital records favors cases with severe 
disease and result in selection bias against asymptomatic or mild disease.  Determining the 
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total population-at-risk was not estimable in this study and the underlying source population 
and referral patterns could shift over time.  
In order to obtain a reportable picture of various outcomes, we created definitions of 
severe versus non-severe, persistence of infection (two and four weeks), attributable 
mortality, and we used the IDSA guidelines to define “appropriate” therapy.  Regardless, the 
overall mortality rate in severe cryptococcosis remains high at almost 25% within one year. 
This study was limited to a single tertiary care center and teaching hospital.  Although 
this could be considered a limitation, evaluating patients at a single center allowed us to 
examine a broader time period with higher uniformity of data availability, continuity of care 
and treatment consistency.  Being a rare disease with high acute mortality, limited numbers 
of cases prevented robust statistical analyses of treatment effects, but to our knowledge this 
study is the largest single-center cryptococcosis cohort study and it provides in-depth 
information on a heterogeneous group of patients.  It represents an important insight into how 
this infection is being managed and what the outcomes have been.  Future studies combining 
our cohort with additional patient groups from other institutions would provide beneficial 
robustness for treatment effectiveness analyses. 
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Table 5.1. Baseline covariates prior to starting antifungal therapy by exposure status (recommended therapy according to IDSA 
Guidelines and flucytosine [5FC] exposure among patients with severe disease). 
 Recommended initial 
treatment 
Recommended initial 
treatment dose 
5FC combination therapy, 
severe only 
5FC (days), severe 2-week 
survivors 
Yes  
n=179 (%) 
No  
n=25 (%) 
Yes 
n=126 (%) 
No 
n=66 (%) 
Yes 
n=101 (%) 
No 
n=28 (%) 
≤7 days 
n=35 (%) 
>7days 
n=81 (%) 
Age >44 yrs.
a
  97 (54) 9 (36) 69 (55) 30 (45) 46 (46) 16 (57) 14 (40) 41 (51) 
Symptoms, ≥14 da 70 (39) 12 (48) 53 (42) 27 (41) 48 (48) 7 (25) 11 (31) 40 (49) 
Severe disease 118 (66) 11 (44) 75 (60) 42 (64) 100 (100) 0 - 35 (100) N/A - 
No symptoms 18 (10) 3 (12) 15 (12) 6 (9) 1 (<1) 0 - 1 (<1) 0 - 
Altered mental status 46 (26) 1 (4) 27 (21) 1 (2) 36 (36) 10 (36) 12 (34) 26 (32) 
Headache  80 (45) 7 (28) 51 (40) 31 (47) 69 (68) 11 (39) 23 (66) 54 (67) 
Cough 33 (18) 7 (28) 25 (20) 13 (20) 13 (13) 6 (21) 6 (17) 10 (12) 
Shortness of breath 29 (16) 11 (44) 26 (21) 12 (18) 8 (8) 7 (25) 5 (14) 8 (10) 
Night sweats 16 (9) 4 (16) 13 (10) 6 (9) 8 (8) 2 (7) 2 (6) 7 (9) 
Fever 72 (40) 12 (48) 52 (41) 24 (36) 45 (45) 14 (50) 14 (40) 36 (44) 
Nausea 57 (32) 5 (20) 38 (30) 19 (29) 39 (39) 11 (39) 15 (43) 33 (41) 
Vomiting 47 (26) 3 (12) 29 (23) 16 (24) 32 (32) 9 (32) 12 (34) 27 (33) 
Seizures 10 (6) 2 (8) 5 (4) 7 (11) 9 (9) 2 (7) 3 (9) 5 (6) 
Weight loss 27 (15) 4 (16) 17 (13) 12 (18) 20 (20) 5 (18) 11 (31) 13 (16) 
Renal insufficiency  28 (16) 4 (16) 21 (17) 8 (12) 14 (14) 3 (11) 4 (11) 13 (16) 
Liver insufficiency  10 (6) 0 (-) 6 (5) 3 (5) 6 (6) 1 (4) 1 (<1) 5 (6) 
Corticosteroid  65 (36) 10 (40) 47 (37) 23 (35) 33 (33) 7 (25) 6 (17) 28 (35) 
Hematologic 
malignancy 
10 (6) 5 (20) 11 (9) 4 (6) 5 (5) 3 (11) 4 (11) 1 (1) 
Non-hematologic 
malignancy 
5 (3) 1 (4) 4 (3) 2 (3) 1 (1) 1 (4) 1 (<1) 1 (1) 
Transplant recipient 39 (22) 3 (12) 30 (24) 9 (14) 15 (15) 3 (11) 3 (9) 15 (19) 
HIV positive 76 (42) 10 (40) 53 (42) 29 (44) 59 (58) 15 (54) 23 (66) 45 (56) 
Exposure to HAART
b
 30 (39) 6 (60) 22 (42) 12 (41) 20 (34) 11 (73) 16 (70) 14 (31) 
a
 Median values for age and duration of symptoms were used to create binary categories. 
b
 Among HIV positive patients only.  Percentages for this variable reflect the total number of HIV positive patients in each column (refer to the row above for 
denominator). 
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Table 5.2. Patient diagnostics at baseline prior to starting antifungal therapy, stratified by to exposure status (recommended therapy 
according to IDSA Guidelines and flucytosine exposure among patients with severe disease). 
 
Recommended initial 
treatment 
Recommended initial 
treatment dose 
Flucytosine combination 
therapy, severe only  
Flucytosine exposure (days), 
severe 2-week survivors 
Yes  
n=179 (%) 
No  
n=25 (%) 
Yes 
n=126 (%) 
No 
n=66 (%) 
Yes 
n=101 (%) 
No 
n=28 (%) 
≤7 days 
n=35 (%) 
>7days 
n=81 (%) 
Positive cultures                 
CNS– first LPa 96 (54) 6 (24) 59 (47) 35 (53) 84 (83) 17 (61) 24 (69) 69 (85) 
Blood 56 (31) 10 (40) 38 (30) 24 (36) 42 (42) 10 (36) 10 (29) 35 (43) 
Pulmonary 39 (22) 7 (28) 29 (23) 15 (23) 7 (7) 3 (11) 3 (9) 8 (10) 
Positive histology 52 (29) 8 (32) 38 (30) 20 (30) 15 (15) 3 (11) 7 (20) 10 (12) 
Serum antigen titer 
≥1:1024 
78 (44) 10 (40) 58 (46) 26 (21) 64 (51) 11 (39) 21 (60) 49 (60) 
First LP
b
                 
CSF antigen 
titer ≥1:1024 
48 (56) 2 (13) 87 (82) 45 (82) 44 (44) 5 (23) 10 (30) 32 (40) 
CSF:Serum 
glucose ratio 
<0.6 
117 (82) 14 (70) 78 (78) 45 (83) 90 (93) 20 (87) 27 (82) 74 (95) 
CSF glucose 
≤40 
69 (45) 6 (30) 47 (44) 20 (36) 58 (58) 16 (67) 18 (53) 52 (64) 
CSF protein ≥45 143 (86) 14 (70) 31 (32) 17 (33) 91 (94) 23 (96) 29 (88) 77 (97) 
Positive India 
ink stain  
61 (44) 1 (5) 36 (37) 23 (46) 55 (63) 6 (2) 11 (35) 44 (60) 
LP OP  ≥20cm H2O
b
  76 (73) 10 (63) 54 (72) 29 (73) 39 (66) 14 (78) 18 (55) 28 (61) 
a
 Lumbar puncture; 176 total patients had an LP performed.  Denominators used for percentages according to exposure (across) were: 85, 15, 106, 55, 101, 23, 33 
and 81 (CSF antigen titer ≥1:1024); 143, 20, 100, 54, 97, 23, 33, and 78 (CSF: Serum glucose ratio <0.6); 153, 20, 107, 55, 100, 24, 34, and 81 (CSF glucose 
≤40); 166, 20, 98, 51, 97, 24, 33, and 79 (CSF protein ≥45); 138, 19, 97, 50, 88, 23, 31 and 73 (positive India ink stain). 
b 
In an effort to capture more opening pressure measurements, maximum LP opening pressure was used for this variable, as first LP did not always measure 
opening pressure.  There were 157 (60%) patients who had an LP opening pressure reading. Denominators used for percentages according to exposure (across) 
were: 104, 16, 75, 40, 59, 18, 33, and 46.   
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Table 5.3.  Initial antifungal regimen by baseline severity of disease 
Antifungal treatment exposures    
Initial therapy  Total (N=204) Severe (n=129) Non-severe (n=75) 
  N (%) n (%) n (%) 
 AmpBd 18 (9) 13 (10) 5 (7) 
 AmpBd+ 5FC 88 (43) 82 (64) 6 (8) 
 ABLC
a 
5 (2) 2 (2) 3 (4) 
 ABLC+5FC 12 (6) 12 (9) 0 - 
 L-AmpB
a
 2 (<1) 2 (2) 0 - 
 L-AmpB +5FC 7 (3) 7 (5) 0 - 
 Fluconazole  71 (34) 10 (7) 61 (81) 
 Other 1 (<1) 1 (<1) 0 - 
Total (appropriate therapy)
b
 179 (88) 118 (92) 61 (81) 
Initial dose
c
  
 
Total (N=192) Severe (n=117)
d
 Non-severe (n=75)
 d
 
  N (%) n (%) n (%) 
 AmpBd (n=98) 54 (55) 50 (57) 4 (36) 
 ABLC (n=15) 13 (87) 10 (9) 3 (4) 
 L-AmpB (n=8) 7 (88) 7 (6) 0 (-) 
 Fluconazole (n=71) 52 (73) 8 (7) 44 (57) 
Total (appropriate dose) 126 (66) 75 (64) 51 (68) 
Therapy changes  Total (N=204) Severe (n=129) Non-severe (n=75) 
  N (%) n (%) n (%) 
 Fluconazole only 60 (29) 3 (2) 57 (76) 
 AmpBd only 60 (29) 53 (41) 7 (9) 
 LFAmpB  only 23 (11) 22 (17) 1 (1) 
 Voriconazole only 1 (<1) 1 (<1) 0 - 
 Fluconazole to AmpBd 9 (4) 6 (5) 3 (4) 
 Fluconazole to LFAmpB   2 (1) 1 (<1) 1 (1) 
 AmpBd to LFAmpB   46 (23) 42 (33) 4 (5) 
 LFAmpB to AmpBd 3 (2) 1 (<1) 2 (3) 
Total (therapy changed) 60 (29) 50 (39) 10 (13) 
a
 ABLC = Amphotericin B Lipid Complex, L-AmpB = liposomal amphotericin B 
b
 Therapy was appropriate (recommended) with respect to the 2010 IDSA Guidelines [1].
  
 
c
 Initial therapy dose was within appropriate (recommended) range for each drug defined by the 
2010 IDSA Guidelines [1].  
d
 Denominators for each drug by severity of disease are n=87, 12, 8, and 10 patients for 
severe disease; n=11, 3, 0 and 61 patients for non-severe disease, respectively.   
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Table 5.4.  Dosing (mg/kg/day) of initial therapy and baseline disease severity among 
patients receiving antifungal therapy and with dosing information. 
 Total (N=192)
b
 Severe (n=117)
c
 Non-severe (n=75)
c
 
Antifungal Therapy
a
 Mean IQR Mean IQR Mean IQR 
Amphotericin B (n=121)       
AmpBd  0.66 0.56 – 0.73 0.66 0.57 – 0.73 0.65 0.48 – 0.84 
ABLC
d
 4.90 4.62 – 5.20 4.86 4.54 – 5.14 5.06 4.80 – 5.47 
L-AmpB
d
  4.28 3.29 – 5.05 4.28 3.29 – 5.05 n/a - 
Fluconazole (n=71) 350 208 – 400 367 400 – 400 346 208 – 400 
a
 Fluconazole dosing is in mg/day.  All other medications are in mg/kg/day.  
b
 12 patients were missing information on initial treatment dose (either dosing or body weight information). 
c 
Denominators for each antifungal drug (top to bottom) are n=87, 12, 8, and 10 patients for severe disease; 
n=11, 3, 0 and 61 patients for non-severe disease, respectively.   
d
 ABLC = Amphotericin B Lipid Complex, L-AmpB = liposomal amphotericin B.
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Table 5.5.  Patient outcomes after antifungal therapy, according to treatment exposure status.  
 Recommended initial 
treatment  
Recommended initial 
treatment dose  
Flucytosine combination 
therapy, severe only  
Flucytosine exposure (days), 
severe, 2-week survivors  
Outcomes Yes  (%) No  (%) Yes (%) No (%) Yes (%) No (%) ≤7days (%) >7days (%) 
Persistence, 2 weeks
a
  
Yes 
No 
52 
53 
(50) 
(50) 
4 
6 
(40) 
(60) 
33 
37 
(42) 
(47) 
17 
19 
(47) 
(53) 
46 
46 
(50) 
(50) 
10 
13 
(43) 
(57) 
16 
19 
(46) 
(54) 
40 
40 
(50) 
(50) 
Persistence, 4 weeks 
Yes 
No 
39 
121 
(24) 
(76) 
6 
16 
(27) 
(73) 
26 
89 
(25) 
(85) 
15 
43 
(26) 
(74) 
29 
60 
(33) 
(67) 
8 
14 
(33) 
(67) 
11 
21 
(34) 
(66) 
26 
53 
(33) 
(67) 
Cryptococcosis-attributable 
mortality 
Yes 
No 
26 
153 
(15) 
(85) 
4 
21 
(16) 
(84) 
12 
114 
(10) 
(90) 
14 
52 
(21) 
(79) 
18 
83 
(11) 
(89) 
8 
20 
(29) 
(71) 
6 
29 
(17) 
(83) 
7 
74 
(9) 
(91) 
One-year mortality 
Yes 
No 
41 
138 
(23) 
(77) 
8 
17 
(32) 
(68) 
26 
100 
(21) 
(79) 
18 
48 
(27) 
(73) 
22 
79 
(22) 
(78) 
12 
16 
(43) 
(57) 
7 
28 
(20) 
(80) 
14 
67 
(17) 
(83) 
Patient re-induced
b
 
Yes 
No 
29 
132 
(18) 
(82) 
5 
17 
(23) 
(77) 
20 
95 
(17) 
(83) 
11 
48 
(19) 
(81) 
22 
71 
(19) 
(81) 
7 
16 
(30) 
(70) 
8 
27 
(23) 
(77) 
21 
60 
(26) 
(74) 
IRIS
c
  
Yes 
No 
6 
155 
(4) 
(96) 
1 
21 
(5) 
(95) 
4 
111 
(3) 
(97) 
3 
57 
(5) 
(95) 
6 
87 
(6) 
(94) 
0 
23 
(0) 
(100) 
1 
34 
(3) 
(97) 
5 
76 
(6) 
(94) 
Renal toxicity
d
 
Yes 
No 
30 
67 
(31) 
(69) 
3 
4 
(43) 
(57) 
23 
42 
(35) 
(65) 
9 
23 
(28) 
(72) 
27 
57 
(32) 
(68) 
6 
14 
(30) 
(70) 
10 
21 
(32) 
(68) 
23 
50 
(32) 
(68) 
a
 Among severe cases only:  2-week persistence: N=115 (13 deaths; 1 missing information), for 4-week persistence; N=182 (5 additional deaths since 2 weeks 
and 3 missing information).   
b
 Patient had to survive through 2 weeks for severe disease and 90 days for non-severe disease (end of recommended treatment duration) to be eligible for 
denominator of re-induction status. 
c
 Immune Reconstitution Inflammatory Syndrome; patient had to survive through 2 weeks for severe disease and 90 days for non-severe disease (end of 
recommended treatment duration) to be eligible for IRIS diagnosis.   
d 
>50% drop in Glomerular Filtration Rate (among severe disease only)—measured from the date closest to the start of therapy (week 0) to the date closest to 2 
weeks after starting therapy (week 2).  Patient had to survive through 2 weeks (end of recommended treatment duration) to be eligible for renal toxicity outcome. 
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Table 5.6  Final adjusted models of the influences of treatment type, dosing, and flucytosine use (severe disease only) on the risk of 
persistence of disease at two weeks (severe disease only) and four weeks (both groups) and mortality hazard.  Persistence outcomes 
were contingent on survival through two weeks and four weeks since the date of starting antifungal therapy. 
 Initial therapy type
a
  Initial therapy dose
b
  Flucytosine
c
   Flucytosine
d
 
Outcomes RR (95% CI)  RR (95% CI)  RR (95% CI)  RR (95% CI) 
Persistence at two weeks (severe only) 1.4 (0.5 – 3.5)  1.1 (0.8 – 1.4)  0.8 (0.4 – 1.6)  0.9 (0.7 – 1.2) 
Persistence at four weeks 1.9 (0.9 – 4.3)  1.1 (0.6 – 1.8)  0.6 (0.3 – 1.3)  0.8 (0.4 – 1.3) 
 HR (95% CI)  HR (95% CI)  HR (95% CI) 
 
HR (95% CI) 
Cryptococcosis-attributable mortality 1.1 (0.4 – 3.2)  2.3 (1.0 – 5.0)  0.5 (0.2 – 1.2)  0.6 (0.2 – 1.8) 
One-year all-cause mortality 0.8 (0.3 – 1.8)  1.3 (0.7 – 2.4)  0.4 (0.2 – 0.9)  1.1 (0.4 – 2.7) 
a 
Patient not given recommended antifungal therapy regimen initially(1) or received recommended therapy (0); Persistence at two weeks adjusted for high 
cryptococcal CSF antigen titer (≥1:1024).  Persistence at four weeks adjusted for high cryptococcal CSF antigen titer (≥1:1024) and severe disease. 
Cryptococcosis-attributable mortality was adjusted for underlying hematologic malignancy and positive blood culture.  One-year all-cause mortality was adjusted 
for confounding by severe disease and underlying hematologic malignancy. 
b
 Patient dose for initial antifungal therapy was outside the range of recommended (1) or dosing was within recommended range (0); Persistence at two weeks 
was adjusted for high cryptococcal CSF antigen titer (≥1:1024). Persistence at four weeks adjusted for severe disease. Cryptococcosis-attributable mortality was 
adjusted for underlying hematologic malignancy, positive blood culture and severe disease.  One-year all-cause mortality was adjusted for confounding by 
positive blood culture and underlying hematologic malignancy. 
c
 Flucytosine was used with initial therapy among severe disease only (n=129).  Persistence at 2 weeks adjusted for high cryptococcal CSF antigen titer 
(≥1:1024); persistence at 4 weeks adjusted for high cryptococcal CSF antigen titer (≥1:1024) and ≥14 days of symptoms prior to presentation; both 
cryptococcosis-attributable mortality and overall mortality adjusted for underlying hematologic malignancy and receipt of amphotericin B deoxycholate. 
d Flucytosine exposure categories were >7 days (referent) and ≤ 7 days of exposure.  Two-week persistence adjusted for high CSF cryptococcal antigen titer 
(≥1:1024) at first LP; four-week persistence adjusted for ≥14 days of symptoms prior to presentation and high initial CSF cryptococcal antigen titer (≥1:1024) at 
first LP; attributable mortality and overall mortality adjusted for underlying hematologic malignancy. 
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Figure 5.1.  Diagram of patient flow scenarios from entry through one year of follow-up.    
Patient enters DUMC, 
cryptococcosis diagnosis 
confirmed, baseline 
severity assessed  
Antifungal 
treatment 
started (to)   
 
Patient cured or 
suppressed with 
maintenance therapy 
Relapse of 
cryptococcosis or 
IRIS 
 
Change, modify 
or restart 
antifungal therapy 
Patient dead (overall 
mortality) or censored at 1 
year from start of therapy or 
end of study 
Attributable mortality: 
patient dies while on therapy 
and/or with persistent 
infection  
Persistent infection assessed 
at weeks two and four after to; 
renal toxicity examined at two 
weeks after to  
“Appropriate” therapy 
exposure assessed based 
on IDSA Guidelines 
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Figure 5.2. Duration of flucytosine combination treatment with initial primary therapy 
(severe disease, n=129) 
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CHAPTER VI.  DISCUSSION 
 
Study summary 
 There were two main goals for this study:  to provide an in-depth description of three 
underlying risk groups with cryptococcosis (HIV-infected, transplant recipients and HIV-
negative, non-transplant) and to investigate antifungal treatment effectiveness from 1996 
through 2009 at Duke University Medical Center.  Importantly, both of these aims were 
developed in order to assess the practical implementation of the 2010 IDSA Guidelines as a 
tool for clinical management of cryptococcosis patients.  In the first aim the three groups 
were described and compared with regard to clinical presentation, immunosuppression, initial 
antifungal therapy and mortality.  Also, global outcomes for utilization of lipid amphotericin 
B as initial therapy as well as trends in frequency of diagnoses between the three groups were 
examined through the 14-year study period.  In the second aim we evaluated the effect of 
initial treatment on the outcomes of persistent cryptococcosis, cryptococcosis-attributable 
mortality and overall mortality through one year from the initiation of antifungal therapy. 
 
The three groups 
 There were notable trends observed between and within each of the three 
cryptococcosis groups.  We found that the mean duration of symptoms reported prior to 
diagnosis was longest in the HIV-negative, non-transplant group. In this group, duration of 
symptoms was approximately three weeks longer among those with severe disease and six 
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weeks longer among patients with non-severe disease compared to the other two groups.  
Between-group means were not all significant.  However among non-severe patients, 
transplant recipients and HIV-negative, non-transplant cases had statistically significant 
different means of symptom duration.  Longer duration of symptoms prior to presentation in 
this latter group was observed in a previous study [68], while another study found a lack of 
significance between HIV-infected, immunocompromised, and immunocompetent groups 
[62].  Greater attention should be placed on barriers to earlier diagnosis, especially 
considering its potential influence on poorer outcome.  Headache, nausea, and vomiting are 
symptoms commonly associated with severe disease, yet in our study HIV-negative, non-
transplant patients with severe disease reported these symptoms markedly less than the other 
two groups.  Altered mental status, another symptom of CNS disease, was similar across the 
three groups in our cohort, while another study reported significantly more mental status 
changes in non-immunosuppressed patients compared to HIV-positive patients [62].  Based 
on our evidence, the absence of indicators for severe disease could be a contributing factor in 
delayed diagnosis in the HIV-Negative, non-transplant group.   
Diagnostic testing by lumbar puncture among severe disease cases revealed that the 
proportion of elevated CSF CRAG titer (≥1:1024) and positive India ink tests in the HIV-
negative, non-transplant group were significantly lower than the other two groups.  Non-
severe disease patients in this group also underwent fewer lumbar puncture tests to rule out 
CNS disease; highlighting the possibility that this group lacks clinical and diagnostic 
evidence of disease that results in delayed diagnosis. This may in turn influence downstream 
outcomes such as attributable mortality.  These diagnostic findings, despite lacking a 
measurable appreciation for burden of organisms, underscore the potential value in the 
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quantification of viable yeasts in the CSF (Colony-forming unit [CFU]/mL measurements). 
Given the relationship of fungal burden to treatment strategy and outcome, understanding its 
rate of change during therapy is important [78,90,123].    
 
Temporal trends 
Case frequencies at DUMC hovered around 15 cases annually, with an apparent shift 
to a decreasing proportion of HIV-positive patients with a concomitant increase in HIV-
negative cases. HIV-positive patients accounted for half of all cases in the first seven years of 
this study then fell to less than one-third in the latter seven years.  As we continue to 
aggressively treat serious underlying diseases with immunosuppressants and the denominator 
of persons-at-risk enlarges, we hypothesize that the HIV-negative, non-transplant group will 
continue to increase given there is currently no strategy for antifungal prophylaxis for this 
population.  There were a consistent number of cases of cryptococcosis in the transplant 
recipients over time despite the widespread use of calcineurin inhibitors, which potentially 
have anti-cryptococcal properties [56,113,114,115,116].  The steady annual prevalence of 
cryptococcosis in this group supports a continued need of careful diagnostic surveillance for 
the early detection of cryptococcosis while patients are on sustained immunosuppressive 
therapy [117]. 
During the 14-year study period, 132 patients (64%) received amphotericin B (either 
formulation) for initial therapy.  Of these 132 patients, AmpBd was used as initial therapy for 
the majority of patients (80%).  Utilization of AmpBd for initial therapy decreased over time, 
indicating that LFAmpB was used more frequently as initial therapy in recent years.  There is 
a lack of studies reporting site-specific annual patterns of initial therapy for the basis of 
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comparison.  Given the approximately one-third of patients who experienced nephrotoxicity 
during management in our study we expect LFAmpB to continue to play an important role in 
anti-cryptococcal therapy.  Further investigation into lipid products of amphotericin B is 
warranted to ensure their optimal use for patients where this formulation is recommended as 
initial therapy, as well as for those who may need to switch to it due to the toxic effects of 
AmpBd. 
 
Persistence, mortality and secondary outcomes  
Among patients with severe disease, persistence was 55% two weeks after starting 
initial therapy then decreased to 33% at four weeks.  Comparatively, among non-severe 
disease patients, persistence was 11% at four weeks.  The percent of patients with disease 
resolution through four weeks falls into the same range of outcomes as previously published 
cohorts [2-5].  Mortality attributable to cryptococcosis was 15% (n=31) and overall mortality 
was 25% (n=52) through one year of follow-up.  Notably, all-cause mortality of severe 
disease patients (26%) was similar to non-severe disease patients (20%), yet when comparing 
attributable mortality, non-severe disease patient mortality (5%) was much lower than severe 
disease patient mortality (20%).  This demonstrates the importance in distinguishing between 
attributable and overall mortality when presenting effect estimates of cryptococcosis on 
patient survival.   
Among patients with severe disease, early attributable mortality during induction 
therapy was high, which limited the analysis of treatment-related effects.  Half of the 26 
severe disease patients who died due to cryptococcosis were within the first two weeks while 
receiving induction treatment; three more died by four weeks.  Non-severe disease patients 
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had much lower mortality, with only three deaths (5%; two attributable to cryptococcosis) 
within the first month of follow-up from the start of initial therapy.   
The HIV-negative, non-transplant group experienced both greater mortality 
attributable to cryptococcosis and overall mortality, accounting for nearly half of all 
attributable deaths and more than half of all-cause mortality.  HIV-infected patients 
accounted for the majority of the remaining deaths.  A recent multi-center study of 86 
cryptococcal meningitis patients also found the highest mortality in the non-
immunosuppressed group (46%), compared to immunosuppressed (19%) and HIV-positive 
patients (15%) [62].  Previous studies have reported 30 – 44% overall mortality in the HIV-
negative population [21,68,69,70].  In one of these studies, this rate was compared to a 22% 
mortality among HIV-positive patients [69].  Of note, some of these studies also included 
C.gatii cases, and factors of that species may have influenced outcome [69,70].   
Renal toxicity and IRIS are important additional outcomes that can be influenced by 
initial antifungal treatment choices and impact subsequent clinical management of the 
patient.  IRIS was identified in all three groups, but the prevalence was low (4%) compared 
to other studies which primarily included only AIDS patients (range, 8–19%) 
[92,93,124,125].   Four out of seven IRIS cases in our study were HIV-infected patients.  
Renal toxicity among patients with severe disease occurred in nearly one-third of cases 
during initial treatment, and 58% of these patients did not complete the recommended 14 
days of induction therapy.  Among the patients surviving at least 14 days, therefore eligible 
to experience switching therapy within the recommended treatment window, there was a 
significant association between switching therapy and evidence of renal toxicity (RRcrude 1.9, 
95% CI:  1.0 – 3.3).   
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Treatment effectiveness 
Our study modeled the effect of three elements of initial treatment exposure 
(recommended drug, dose, and flucytosine combination therapy) on three outcomes—
persistence, attributable mortality and overall mortality.  We found that the administration of 
recommended initial treatment in this retrospective cohort adhered consistently to the IDSA 
Guidelines, with an appropriate therapeutic regimen being used for 88% of patients and the 
recommended dosing being followed as recommend in 66% of patients.   
Our results of this support the current IDSA Guideline bearing in mind the limited 
number of cases and retrospective nature of this study.   For instance, not receiving the 
recommended antifungal regimen initially was associated with a higher relative risk of 
persistent infection at four weeks (RR1.9, 95% CI 0.9 – 4.3).  Also the risk of attributable 
mortality among those not receiving the recommended dose of initial therapy was higher 
relative to those receiving appropriate dosing (RR 2.3, 95% CI 1.0 – 5.0).  Over one-third of 
patients changed from their initial therapy; 28% of these patients were switched from a non-
recommended to a recommended therapy based on their disease severity.  The consequences 
of this change in therapy resulted in patients who experienced an overall longer duration of 
treatment compared to those who did not.  Future studies should further examine how a 
patient’s length of induction therapy is influenced by changing amphotericin B formulations, 
which could be a consequence of toxicities rather than persistence of disease. 
Flucytosine was used in 78% of severe disease patients for combination therapy, but 
only 37% of these recipients continued combination treatment for at least 14 days as 
recommended.  Renal toxicity likely contributed to early cessation of flucytosine therapy.  
Flucytosine exposure was associated with a lower overall mortality rate (HR 0.4, 95% CI 0.2 
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– 0.9); ≥7 days of exposure was associated with a lower rate of attributable mortality relative 
to those with 0 – 7 days of flucytosine with initial treatment (HR 0.6, 95% CI 0.2 – 1.8).  
This observation stresses the importance of exposure to combination therapy with polyene 
and flucytosine, and supports a growing body of evidence that this fungicidal regimen is 
critical for treatment success.  The polyene and flucytosine combination has demonstrated its 
superior success based on evidence from retrospective data identifying better outcomes at 
two weeks [4], prospective randomized trial data on fungicidal activity in the CSF [78], and 
correlation with this fungicidal activity and outcome [87,131].   
 
Conclusions  
This study of “real world” clinical management of cryptococcosis revealed some 
important observations.  Unfortunately, acute mortality remains a serious concern.  Future 
clinical studies should focus on earlier identification, diagnosis and treatment, as well as 
strategic clinical management of this high-risk group.  Additionally, sustained flucytosine 
combination therapy was inconsistent among severe disease patients in this study.  Longer 
exposure to combination antifungal therapy resulted in lower rates of mortality relative to 
patients receiving little or no flucytosine.  Our study emphasized the need for clinicians to 
use flucytosine more consistently.  In order to assess therapeutic dosing, rapid access to 
serum flucytosine levels could improve adherence and potentially avoid issues of toxicity.  
Due to our findings regarding the importance of remaining on flucytosine combination 
therapy to reduce patient morbidity and mortality, further investigation into factors 
contributing to toxicity is warranted.  Renal toxicity was common and negatively influenced 
completion of antifungal therapy.  In these cases, lipid formulation amphotericin B may be a 
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better alternative for initial primary therapy to amphotericin B deoxycholate, as changing 
during induction treatment can lead to longer durations of therapy and greater costs.   
Our description of the three groups with cryptococcosis revealed that HIV-negative, 
non-transplant patients had a longer duration of symptoms prior to presentation.  In this 
group a fewer proportion of patients presented with symptoms and/or diagnostics indicating 
severe disease.  These factors could have contributed to delayed diagnosis and poorer 
outcomes observed relative to the other two groups.  HIV-negative, non-transplant patients 
experienced the highest mortality, and hematologic malignancy was strongly associated with 
patient mortality in our cohort.  This likely reflected the end-stage of the underlying disease 
when cryptococcosis was diagnosed [111,115].  More studies of this group are needed in 
order to identify background rates of cryptococcosis, baseline risk factors, and symptoms for 
earlier diagnosis.  Additionally, it would be valuable to assess present treatment strategies 
and their relationship to changes in fungal burden, so as to reduce poor outcomes in this 
population.   
Out of the four initial treatment exposure and patient outcome categories modeled in 
this study, there were some notable findings.  First of all, not receiving the recommended 
initial therapy was associated with an increased risk in persistence at four weeks relative to 
the risk among those who received recommended therapy.  Additionally, not receiving the 
recommended initial therapy dose was associated with a higher mortality hazard rate relative 
to receiving the recommended dose.  Furthermore, receiving flucytosine combination therapy 
for initial treatment as recommended for severe disease patients was associated with a lower 
mortality hazard rate relative to those only receiving amphotericin B.   
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Antifungal therapy approaches used in our medical center were largely concurrent 
with the treatment algorithms provided by the IDSA Guidelines.  Most patients with severe 
disease received amphotericin B for initial treatment and the majority of non-severe patients 
received fluconazole as primary therapy.  While we summarized the intricacies of stopping 
and changing treatment choices in our study, due to limited sample size, we did not examine 
the causal effects of switching therapy on patient outcome.  Nonetheless, examining initial 
therapy exposures yielded valuable insights into the treatment approaches used for 
cryptococcosis across patient groups with various underlying conditions and disease 
presentations.  The future of cryptococcosis treatment and the development of new antifungal 
therapies should not only be informed by randomized trials, but also by key observational 
trends that help to identify problematic applications of drug regimens to diverse populations.  
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APPENDIX A.  PATIENT ABSTRACTION FORM 
 
 
Study Number__________ 
(Write this number in upper right hand corner of every page) 
 
 
Cryptoccocus infections in the era of lipid formulation of amphotericin B 
Database form 
(This front sheet will be torn off after data entry and stored separately to de-identify patients) 
 
Patient name (not to be entered in database):_____________________ 
History Number (not to be entered into database): __________________ 
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All the information from hospital admissions and follow ups will be documented if these 
were related directly to cryptococcal infections. 
Please duplicate tables if need more space.   All dates should be entered as “mm/dd/yy.” 
 
 
 
 
 
 
Subsequent Admissions (with Crypto dx on discharge): 
2. Date of Hospital Admission (MM/DD/YY): ______/_______/_______ 
Date of Hospital Discharge (MM/DD/YY): ______/_______/_______ 
3. Date of Hospital Admission (MM/DD/YY): ______/_______/_______  
Date of Hospital Discharge (MM/DD/YY): ______/_______/_______ 
4. Date of Hospital Admission (MM/DD/YY): ______/_______/_______  
Date of Hospital Discharge (MM/DD/YY): ______/_______/_______ 
5. Date of Hospital Admission (MM/DD/YY): ______/_______/_______  
Date of Hospital Discharge (MM/DD/YY): ______/_______/_______ 
6. Date of Hospital Admission (MM/DD/YY): ______/_______/_______  
Date of Hospital Discharge (MM/DD/YY): ______/_______/_______ 
7. Date of Hospital Admission (MM/DD/YY): ______/_______/_______  
Date of Hospital Discharge (MM/DD/YY): ______/_______/_______ 
8. Date of Hospital Admission (MM/DD/YY): ______/_______/_______  
Date of Hospital Discharge (MM/DD/YY): ______/_______/_______ 
 
Geographical location:  Where does patient live at time of Dx?  
(Example: Durham, NC) _________________  Country (if not US) ____________ 
Primary Discharge diagnosis 
⁮CNS cryptococcus infection          ⁮ Pulmonary Cryptococcus infection      
⁮Crypto infection at other site, Specify: _______________ 
Demographic information 
Age (at time of diagnosis): ____________ Sex: ⁮ M     ⁮ F 
Birthdate: _____/_____/________ 
Race/ethnicity:   
 African American ⁮    Caucasian⁮    Hispanic⁮      
 Asian ⁮     American Indian ⁮      Other ⁮            
Unknown⁮ 
Weight*:_______________________ Date taken: ______/_____/________ 
*important for those who received flucytosine 
First Date of Hospital Admission (MM/DD/YY)*: ______/_______/_______  
Date of Hospital Discharge (MM/DD/YY): ______/_______/_______ 
 Or  
Date of Death (MM/DD/YY): ______/_______/_______ 
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IMMUNE STATUS 
     
HIV Status on admission           
  positive⁮                    negative ⁮                    unknown ⁮ 
Diagnosis of HIV made during this admission           yes ⁮                              no ⁮          
Date of HIV Diagnosis: _________/_________/_________                     
Antiretroviral therapy prior to 1
st
 admission for Crypto?   
  Yes ⁮                            no⁮   
If yes please list the name of antiretrovirals:_______________________________________    
 
Evidence of noncompliance*                                                    
  Yes ⁮                             no ⁮                         
 
Last CD4 count prior to therapy for cryptococcus _____________ 
Date:_____/_____/______                        
 
Please list all CD4 counts after Cryptococcus diagnosis was made.  Circle Yes or No 
when applicable. 
CD4 count Date 
(mm/dd/yy) 
Still on Crypto therapy 
(Y/N) 
ARV therapy (Y/N) 
    Y              N               Y              N 
    Y              N   Y              N 
    Y              N   Y              N 
    Y              N   Y              N 
    Y              N   Y              N 
    Y              N   Y              N 
 
Notes:  
*if the patient has a history of noncompliance with regard to HIV therapy, please 
briefly describe here.
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**IF NOT A TRANSPLANT PATIENT, SKIP PART C** 
C. Transplant Status: 
1. Transplanted organ      Yes⁮             No ⁮ 
 Renal ⁮       Cardiac ⁮     Pulmonary ⁮     Liver⁮       Pancreas⁮     Heart-lung⁮ 
Date of transplant _____/_____/_________ 
 
2. Stem Cell Transplant Recipient  Yes⁮             No ⁮ 
  Allo ⁮       Auto ⁮    Cord Blood ⁮    
 Date of Transplant: _________________ 
Did the patient have GVHD within 6 months of diagnosis:   Yes⁮             No ⁮    
 
Type of immunosuppression: 
 Calcineurin inhibitor ⁮     glucocorticoid   ⁮     MMF ⁮    AZA ⁮    Methotrexate ⁮ 
 Monoclonal antibodies (please specify which e.g alemtuzumab(campath), antiTNFalpha 
antibodies, daclizumab, OKT3, Rituximab or other) ⁮_______________________ 
 Sirolimus ⁮ 
Type of calcineurin inhibitor:   cyclosporine ⁮              tacrolimus ⁮           
Type of steroid: ___________________    
Daily dose of steroids the day of Cryptococcus diagnosis: ______________________ 
Other immunosuppressants: _____________________________________________ 
Duration of immunosuppressant up to diagnosis of crypto: _____________________  
Date of starting immunosuppressant: _______________________                                
 
  
  
 
118 
D. Other causes for immunosuppression  
 Steroid therapy ⁮          Immunosppressants (other than steroids) ⁮      
Chronic organ failure:    renal ⁮      hepatic⁮         rheumatologic disorder ⁮     
  chronic lung disease ⁮            hematologic malignancies⁮       other malignancies⁮      
  Other:_______________________________ 
 
Type of immunosuppression: 
 Calcineurin inhibitor ⁮     glucocorticoid   ⁮     MMF ⁮    AZA ⁮ 
  Sirolimus ⁮  Methotrexate ⁮   
 Monoclonal antibodies (please specify which e.g alemtuzumab(campath), antiTNFalpha 
antibodies, daclizumab, OKT3, Rituximab or other) ⁮___________________________ 
Type of calcineurin inhibitor:  cyclosporine ⁮              tacrolimus ⁮           
Type of steroid ______________ 
Daily dose of steroids at time of treatment___________ 
 Other immunosuppressants_____________________________ 
Duration of immunosuppressant up to diagnosis of crypto:__________________ 
Date of starting immunosuppressant:________________________ 
 
E. Changes made in immunosuppressants after diagnosis of cryptococcal infection 
Was immunosuppressive therapy weaned during cryptococcal therapy:     Yes ⁮  No ⁮     
If yes, which agent was dose-reduced: _______________________ Date: ____________ 
Drug concentrations while receiving anti-crypto therapy (list): __________________ 
____________________________________________________________________ 
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DIAGNOSIS   
Physical Findings/Symptoms on admission/diagnosis 
1. General     Night sweat⁮   Weight loss⁮   Fever ⁮Temperature if measured: _______  
Nausea⁮   vomiting ⁮  
 Other:__________________________________________________________________ 
2. CNS/neurological   Papilledema     Altered mental state        cranial neuropathy ⁮    
Hearing loss⁮    Meningismus Behavioral changes Seizures⁮       
Cerebellar signs⁮      Headache       memory changes ⁮  Pathologic reflexes⁮ 
 Other:__________________________________________________________________ 
3. Respiratory    Cough⁮         Shortness of breath⁮      Pleuritic chest pain ⁮      
  Other:__________________________________________________________________ 
4. Skin       papules/nodules⁮                    cellulitis ⁮       
  Other:__________________________________________________________________ 
5. Other:__________________________________________________________________ 
Head CT findings  
Date: _____/____/_____       
CT with contrast ⁮      CT without contrast ⁮  
Meningeal enhancement ⁮      intraparenchymal lesion⁮   increased intracranial pressure 
  not tested ⁮       normal⁮ 
 Other:__________________________________________________________________ 
MRI findings  
Date: _____/____/_____       
Meningeal enhancement ⁮    intraparenchymal lesion⁮   
 increased intracranial pressure ⁮      not tested ⁮       normal⁮ 
  Other:_________________________________________________________________ 
Chest Xray (First documented after crypto diagnosis)  
Date: _____/____/_____       
 Effusion ⁮          intraparenchymal mass ⁮    atelectasis ⁮         lymphadenopathy⁮      
 Normal ⁮    Not tested ⁮                 Not related⁮               
  Other:_________________________________________________________________ 
CT chest (First documented after crypto diagnosis)  
Date: _____/____/_____       
 Effusion ⁮        intraparenchymal mass ⁮       atelectasis           lymphadenopathy⁮      
 Normal ⁮    not tested ⁮                 not related ⁮    
 Other:___________________________________________________________________ 
Histology 
Biopsy ⁮                          BAL( bronchoalveaolar lavage) ⁮    
Date: _____/____/_____       
Site of biopsy:  lung ⁮        Skin  ⁮             Brain⁮        Other:___________________   
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If brain biopsy specify: open brain bx  ⁮                    Needle biopsy ⁮    
If lung biopsy specify: open thoracotomy  ⁮               Needle biopsy   ⁮  thoracoscopy⁮ 
Describe histology findings as reported: 
_________________________________________________________________________ 
 
  
   
 
 
1
2
1 
Lumbar Puncture Data (Please include all available LP after cryptococcus diagnosis) 
Date 
(mm.dd.yy) 
Opening 
pressure◦ 
(in cm of 
water) 
Number of 
nucleated 
cells 
Number 
of RBC 
glucose protein Antigen 
titer 
Culture  Days 
positive after 
culture* 
India 
ink 
Minimal 
inhibitory 
concentration 
( MIC) 
 
 
          
 
 
          
 
 
          
 
 
          
 
 
          
 
 
          
*Days between when the LP was done and when CSF culture became positive (Consider a month to be 30 days) 
◦ If opening pressure was not measured please write NM =  “Not measured” 
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Serum cryptococcus antigen (Please document all available data after initial crypto 
diagnosis) 
Date_____/____/_____ titer_________ detected⁮        not detected⁮            not tested⁮    
Date_____/____/_____ titer_________ detected⁮       not detected⁮             not tested⁮    
Date_____/____/_____ titer_________ detected⁮       not detected⁮             not tested⁮    
Date_____/____/_____ titer_________ detected⁮       not detected⁮             not tested⁮    
Date_____/____/_____ titer_________ detected⁮       not detected⁮             not tested⁮    
Date_____/____/_____ titer_________ detected⁮       not detected⁮             not tested⁮    
 
Fungal cultures (other than CSF) for cryptoccocus  at the time of diagnosis, treatment 
induction or relapse 
1. Blood         Not checked⁮       Nbr of positive cxs____      Nbr of negative cxs ____   
Dates of positive cxs _____/____/_____, _____/____/_____, _____/____/_____ 
Dates of negative cxs_____/____/_____, _____/____/_____, _____/____/_____ 
               
2. Pulmonary    Not checked⁮     Nbr of positive cxs____      Nbr of negative cxs ____   
Dates of positive cxs _____/____/_____, _____/____/_____, _____/____/_____ 
Dates of negative cxs_____/____/_____, _____/____/_____, _____/____/_____ 
 
3. Other sites with cultures positive for cryptococcus (please specify with corresponding 
date (mm/dd/yy):________________      
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COMORBIDITIES 
Infections during or after diagnosis of crypto (During diagnosis or while on treatment) 
Organism Date of 
diagnosis 
Site of 
culture 
Antigen test 
(Y/N) 
Name of Antibiotics 
     
     
     
     
     
     
     
     
     
     
     
     
 
Were malignancies diagnosed during or after diagnosis of crypto (during diagnosis or 
while on treatment)? 
 Yes ⁭               No ⁭ 
If yes, specify  
Type of malignancy:__________________________ 
Site of malignancy:____________________________ 
Date of diagnosis:______/______/_______ 
Treated?    Yes⁭              No ⁭Agent for treatment:_______________________________ 
 
TREATMENT                                           
Please fill the following table starting with the first encounter:         
Drug Date of 
Initiation 
Daily Dose Date of 
stopping  
Cumulative 
Dose  
Flucytosine     
     
     
     
AmB-d     
     
     
     
L-AmB     
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ABLC     
     
     
     
Fluconazole     
     
     
     
Other:      
Change row with each dose switch. Data can be entered from multiple admissions or follow 
ups. 
 
Flucytosine 
Date          Serum 
Concentration 
  
  
  
 
  
Short-term Outcomes: 
 
 
Renal function (fill in all that applies)  
Date of value 
followed by Cr 
value 
Creatinine 
on 
admission 
Cr at the end of 
Amphotericin 
B 
deoxycholate 
Cr at end of 
amphotericin 
B lipid 
product  
Maximum creatinine 
on admission while on 
treatment with polyene 
therapy 
Date     
Value (of Cr at 
date above) 
    
Date     
Value     
* Please duplicate table if reinduction with amphotericin products 
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Hematologic parameters: 
 Hemoglobin Hematocrit Platelets WBC 
Value at onset of induction treatment 
w/ flucytosine 
Date:_____/_____/______ 
    
Value at 2 weeks after treatment w/ 
flucytosine 
Date: _____/_____/______ 
    
 
1. Did the patient receive polyene therapy?   Yes⁮          No⁮        Unknown ⁮ 
a) What was the initial polyene therapy?       deoxycholate ⁮                  lipid preparation 
b) Did the patient have to switch antifungal therapy (from deoxycholate to a lipid 
preparation) as a result of drug toxicity or side effect?         
 Yes⁮                  No⁮ 
 If so, what toxicity or side effect:    infusion related⁮            renal dysfunction⁮      
⁮   Other_________________________________________________________________ 
 
2. Did the patient have to switch antifungal therapy secondary to poor clinical 
response?  
 Yes ⁮                 No ⁮ 
 From deoxycholate to a lipid formula ⁮                 
 From lipid formula to deoxycholate ⁮ 
 From fluconazole to amphotericin B ⁮ 
  Other: 
____________________________________________________________________ 
 
Reason for switch (circle):   Persistent symptoms/physical findings ⁮     
 Persistent cultures⁮          Persistent antigen in CSF ⁮   Persistent antigen in serum ⁮ 
 
Antiretrovirals and Antifungals 
Was antiretroviral therapy continued along with antifungals during admission for crypto? 
 Yes ⁮      No⁮ 
Was antiretroviral therapy held during admission for crypto?   
 Yes ⁮      No⁮ 
If held during admission was antiretroviral therapy restarted on discharge:   
 Yes ⁮      No⁮ 
Was antiretroviral therapy started newly after diagnosis of crytpococcal infection during the 
admission for crypto?   
 Yes ⁮      No⁮   
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Was antiretroviral therapy started newly after diagnosis of crytpococcal infection on 
discharge?   
 Yes ⁮      No⁮       
Was antiretroviral therapy planned to be started newly after diagnosis of crytpococcal 
infection after discharge?   
 Yes ⁮      No⁮                                              
 
 Name of antiretroviral medications that was newly started and date on which it was started 
(mm/day/yy): 
1.______________________________  Date_______/_______/________ 
2.______________________________ Date_______/_______/________ 
3.______________________________ Date_______/_______/________ 
 
Management of increased intracranial pressure (if present) 
A. Repeated lumbar punctures:  Yes   ⁮  No ⁮   
B. Lumbar drain:     Yes   No ⁮ 
Time from diagnosis of increased ICP (OP>20cm water) to lumbar 
drain:_________________ 
Date of insertion: _______/_______/________ 
C. Ventricular shunting:    Yes  No ⁮     
Time from diagnosis of increased ICP (OP>20cm water) to ventricular 
shunting:___________ 
Time from starting antifungal therapy to ventricular shunting:____________________ 
Date of procedure: _______/_______/________ 
D. Pharmacological therapy:             Yes         No ⁮   
Medication used: Acetazolamide ⁮               Corticosteroids (newly started for that reason) ⁮ 
Others ⁮ ________________________________________________ 
 
Long-term outcomes: 
Date of last follow up: _______/______/______ 
Outcomes: (Documented on last available follow up) 
⁮    Cure (pt off drugs and resolved symptoms)   
   Improved  
   Stable on therapy 
   Persistence defined by:    
 Persistence of symptoms       ⁮    Positive Antigen (CSF or serum)   ⁮  
 Positive culture   
 Relapse defined by following after initial sx and cultures resolved 
 Reappearance of symptoms       ⁮  
 Positive culture   ⁮   
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 Death directly related to crypto infection 
 Indeterminate (lost to follow up) 
 
In patients with organ transplant were they diagnosed with TRANSPLANTED organ 
failure before, during or after Cryptococcus treatment?  
 Yes   ⁮No     Indeterminate 
If yes please specify:     Before⁮      During⁮        After cryptococcus treatment⁮  
Was the patient re-transplanted?  
 Yes ⁮      No⁮      
Date of re-transplant:____/_____/______ 
Were they on antifungal treatment on time of re-transplant?  
 Yes⁮        No ⁮ 
Did the patient have persistent organ failure secondary to antifungal treatment? ⁮   
 Yes     ⁮  No 
If yes please specify: Liver failure ⁮      Kidney failure ⁮        Bone marrow suppression⁮ 
    
Diagnosis of immune reconstitution syndrome made during hospital stay 
 Yes ⁮                             No ⁮  
Was Immune Reconstitution Syndrome treated?    
 Yes⁮              No⁮ 
If yes please specify what medication was used for treatment: _________________________ 
If steroids were used please specify: 
Name of steroid___________________________________    
Daily Dose______________________________________    
Starting date_______/_______/________ 
Stopping date_______/_______/________ 
Criteria used for diagnosis: New appeareance or worsening of any of the following: 
 Clinical or radiographic manifestations consistent with an inflammatory process such as 
contrast enhancing lesions on imaging studies (CT/MRI) ⁮ 
 CSF pleocytosis>5WBC ⁮ 
 Increased ICP ⁮ 
 Histopathology showing granulomatous lesions ⁮ 
 Unexplained hypercalcemia ⁮ 
AND 
 Symptoms occurred during receipt of appropriate therapy and could not be explained by 
newly acquired infection ⁮ 
AND 
 Negative results for cultures or stable/reduced biomarkers for the initial fungal pathogen 
during diagnostic work-up for the inflammatory process ⁮        
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MORTALITY: ⁮   yes    ⁮  no          n/a 
Date of death: ______/______/________ 
Cause of death: 
Attributable to Cryptococcus       ⁮   Yes ⁮   No 
If yes, was it identified as related to the following? 
⁮  Increased CNS pressure   
⁮  Persistent infection        
⁮  After end of treatment   
     Organ failure secondary to Cryptococcus treatment  
⁮  while on treatment for crypto of underlying disease     
⁮  Indeterminate  
⁮  Other_____________________________________          
 
Notes:
  
1
2
9 
Summary Timeline for CLINICAL OUTCOMES: 
 Date 
Of last clinical 
assessment* 
Hospitalized 
(H) 
Home (HM) 
SNF  
#  of hospital 
readmissions 
(since last assessment)  
On Tx 
(y/n) 
Reinduced 
with 
antifungal 
therapy(Y/N) 
Creatinine 
 
2Weeks       
10 weeks       
1 Year       
> 1 Year       
*If still hospitalized from primary adm, please use date at specified week or last available prior date 
 
 Old sx still 
present 
(specify 
which) 
New sx 
appeared 
(specify  
which) 
Old sx 
resolved 
(specify  
which) 
Imaging findings 
( CT brain, MRI brain, X 
ray chest, CT chest) 
Improved 
(I) 
Stable (S) 
Worse (W) 
Provider performing the follow up 
(PCP, ID,neuron, pulm) 
2 
weeks 
 
      
10 
weeks 
 
      
1 year 
 
      
>1 year 
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APPENDIX B.  CUMULATIVE ANTIFUNGAL DOSING 
Table B.1.  Cumulative dose of uninterrupted initial therapy for patients who survived 
through two weeks (severe) or 90 days (non-severe). 
Initial Therapy 
Median cumulative 
 dose* (mg/kg) Range 
Severe cryptococcosis  
AmpBd (n=17) 
ABLC (n=5) 
Liposomal AmpB (n=4) 
Fluconazole (n=1) 
 
9 
64 
54 
146000 
 
1 - 35 
45 – 92 
5 – 163 
n/a 
Non-severe cryptococcosis 
AmpBd (n=3) 
Fluconazole (n=16) 
 
17 
30100 
 
10 – 24 
4116 – 14000 
*Fluconazole cumulative dose is in total mg. 
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